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Executive Summary
Background
• Ireland has one of the highest rates of mortality from cardiovascular
disease in Europe. Time to medical treatment is crucial in the
management of Acute Coronary Syndromes (ACS).
• The aim of the present study was to provide an overview of the current
patterns of presentation and management of ACS in Ireland. Treatment of
both acute myocardial infarction (AMI) and other ACS patients was
assessed. Findings were compared to a previous national survey
conducted in 1994. The prevalence of depression post-ACS event was
also assessed.
Method
• Following ethical approval, all relevant hospitals nationally (N=39)
provided data on 25 consecutive suspected AMI patients admitted to
I/CCU. Information was also collected on suspected other ACS patients
admitted to I/CCU within that time.
• Patients provided informed consent while in I/CCU. Clinical and
management information was subsequently obtained from hospital
records. Patients also completed a self-report depression questionnaire.
• Total sample obtained was 1365 patients (935 suspected AMI and 430
suspected other ACS patients).
Results
• The patients’ demographic profile was similar to the 1994 sample. Every
patient admitted had at least one of the following risk factors: smoker or
ex-smoker (72%), prior CHD history (43%), raised total cholesterol (12%)
(or low HDL cholesterol – 37%), positive family history of CHD (44%), or
diabetes (15%).
v• Total cholesterol levels were measured in 88% of patients admitted.
Triglycerides, HDL and LDL levels were recorded in 83%, 53% and 51%
of patients respectively.
• Median ‘door-to-needle’ time for thrombolysed patients has been reduced
from 76 minutes in 1994 to 45 minutes in 2003 (a 41% reduction in nine
years). Twenty-nine per cent of eligible patients were thrombolysed within
the recommended time of 90 minutes from call for professional help.
Thirty-five per cent of eligible patients receive thrombolysis within the
recommended time of 30 minutes of arrival at hospital.
• A major shift in the location of thrombolysis administration has occurred. In
1994, 96% of thrombolysis occurred in I/CCU with 2% in the Emergency
Department. In 2003, 48% was in the Emergency Department and 48% in
I/CCU. Thirty-six per cent of hospitals provided thrombolysis to ≥80% of
those receiving this treatment in the Emergency Department. Time to
thrombolysis was significantly shorter when delivered in the Emergency
Department than in I/CCU (median 35mins v 60mins, p<.001).
• Fewer confirmed AMI patients were provided with thrombolysis in 2003
than in 1994 (44% v 58%). This may be due to changes in definition of
ACS over this time.
• Hospital arrival to I/CCU admission times were lengthy for those patients
who were not eligible for thrombolysis (median 2h 15mins). A longer
symptom onset to hospital presentation time was seen for suspected AMI
patients who did not subsequently receive thrombolysis (5h 00mins v 2h
15mins, p<.0001).
• Patients who were referred by a GP took significantly longer to present to
hospital (5h 03mins v 2h 48mins, p<.0001). Those who lived further away
from hospital were more likely to present to a GP first, as were patients
who were experiencing AMI for the first time.
vi
• No significant impact on hospital presentation time was seen for patients
presenting with suspected AMI who had a prior history of AMI.
• Time from onset of symptoms to hospital arrival has not improved since
1994 (3h 35mins in 2003 v in 3h 30mins in 1994). This factor is the largest
contributor to delayed time to treatment for AMI and other ACS.
• A greater percentage of suspected AMI patients were confirmed as AMI
in 2003 than 1994 (91% v 70%). There was a corresponding decrease in
diagnoses of unstable angina (4% v 14%). This may be attributable to
recent changes in definition of ACS.
• Prescription of cardiovascular medications fell below recommended levels
for statins (73%) and beta-blockers (66%), but not for anti-platelets (85%).
• Significant levels of depression were found post-ACS event (17-22%). The
use of short-form self-report depression scales was found to be a feasible
option in an acute setting.
• Seventy per cent of patients were recorded as having been referred to
Phase I (hospital inpatient) cardiac rehabilitation.
Recommendations
Recommendations from this study are made in the context of the development of
an ongoing system of assessment of ACS – the Coronary Heart Attack Ireland
Register (CHAIR). Thus the focus is on specific recommendations particular to
the findings in this survey. More general issues such as the need for unique
patient identifiers to track patients throughout the healthcare system are not
addressed.
Pre-hospital phase
1. Strategies to reduce pre-hospital time to treatment need to be developed
or expanded. These may include GP thrombolysis, emergency medical
technician (EMT) thrombolysis or mobile coronary care units (MCCUs).
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2. Strategies to increase the administration of aspirin in the pre-hospital
phase should be developed. In the pre-hospital phase 9% of patients
received aspirin from GPs, 4% in the ambulance and 2% of patients self-
administered aspirin.
3. Strategies to reduce time from onset of symptoms to patients’ call for help
should be considered on the basis of available evidence. Of particular
note are strategies which would encourage prompt and appropriate
action by those with a previous cardiac event.
Hospital phase
4. A policy of thrombolysis for all eligible patients in the Emergency
Department should be considered. Patients should be assessed as to
whether they should be transferred for direct infarct angioplasty or
receive thrombolysis.
5. Support should be provided to increase availability of direct infarct
angioplasty facilities. Four per cent of suspected AMI patients in the
current survey received this treatment.
6. Recommended times to treatment (90 minutes from call to professional
help, 30 minutes from hospital arrival) should be adopted with centres
monitoring the proportion of patients achieving these targets on an
ongoing basis.
7. The measurement of cholesterol for suspected ACS patients should be
adopted as standard.
8. Further research should evaluate the clinical value of screening patients
for depression in the acute phase of an ACS event.
Post-hospital phase
9. Prescription of cardiovascular medications post-ACS should adhere to
current professional guidelines.
viii
10. Referral for cardiac rehabilitation services should be undertaken for all
patients in line with professional guidelines.
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1Chapter 1
Introduction
1.1 General introduction
Ireland has one of the highest mortality rates from cardiovascular disease in the
European Union (EU).1 These rates are at an intermediate level between the rest
of the EU and the high rates in former Eastern Bloc countries. Approximately
50% of acute myocardial infarction (AMI) deaths in the community occur within
two hours from the onset of symptoms.2 Early management of AMI patients with
revascularisation (e.g. thrombolytic therapy) improves prognosis.3 Therefore,
shortening of time to treatment for AMI patients is an important life-saving goal
for the health services.
International guidelines, e.g. from the European Society of Cardiology4 5 and the
British Heart Foundation6 have proposed a ‘call-to-needle’ time of 90 minutes for
thrombolysis administration. The National Service Framework (NSF) in the
United Kingdom (UK) further reduced the recommended time in 2000 with a
proposed ‘call-to-needle’ time of 60 minutes.7 In Ireland, the 1994 national
census found a median time to treatment of 4 hours 30 minutes.8 This compares
unfavourably to more recently recorded median treatment times in other
countries (2 hours 45 minutes in the UK9; 2 hours 54 minutes in Switzerland10).
Since 1994, there has been no examination of time to treatment and the extent to
which international guidelines for treatment of AMI are being achieved in Ireland.
An acute coronary syndromes register (CHAIR - Coronary Heart Attack Ireland
Register) is at the pilot stage in the Southern Health Board. Given the importance
of contemporary data to target the investment of resources and finances, an
update on the time to treatment for AMI was considered appropriate. The present
research addresses Recommendation 8.5 of the Cardiovascular Health
Strategy2: Pending the implementation of a national coronary care information
system, a further census of CCUs should be undertaken to assess the extent to
which thrombolysis is being given within the time recommended internationally.
21.2 The present study and the Cardiovascular Health Strategy
As specified in the call for research proposals under the Cardiovascular Health
Strategy in 2001, this proposal focused on repeating the previous censuses but
also incorporated additional information which can be used to inform the
establishment of a national coronary care information system, and provide up-to-
date information on other treatments and interventions.
The study also meets the Cardiovascular Health Strategy aim of engaging health
professionals in monitoring, clinical audit and evaluation of their work, by
involving a wide constituency and aiming to include all relevant centres. By giving
a commitment to the provision of a national summary report, alongside a
confidential outline of data from each participating centre, it enables participants
to consider their own performance vis-à-vis national and international patterns.
This study follows two previous national audits of patients admitted with
suspected AMI to Intensive Care Units/Coronary Care Units (I/CCUs). These
were undertaken in 1992 and 1994.8 11 As part of the study, the work builds on
previous and existing projects currently under way in a number of centres and
will be used to inform the development of initiatives such as CHAIR.
The present CCU 2003 study differed from previous Irish research in several
aspects. Since the definition of acute events has expanded and become more
specific, CCU 2003 broadened its inclusion criteria from suspected AMI to
suspected acute coronary syndromes (ACS). ACS includes AMI and unstable
angina – in this way it is possible to compare the current data with the previous
data, but also to extend the relevant findings to treatment for other ACS. New
treatment regimes and aspects of treatment are examined that were not as
widely available in 1994, e.g. percutaneous coronary interventions (PCI), low-
density lipoprotein (LDL) cholesterol measurement, statin therapy, and cardiac
rehabilitation programmes.
CCU 2003 also examines the psychological well-being of patients during their
hospital admission. Depression is an independent risk factor for increased post-
myocardial infarction morbidity and mortality, even after controlling for the extent
3of coronary artery disease, infarct size, and the severity of left ventricular
dysfunction.12
The objectives of the present study were to:
 document aspects of the process of care for patients admitted to
hospital with suspected ACS
 compare the findings with previous management as documented in
the 1994 census
 identify the extent of adherence to recognised guidelines on the
immediate care of patients with ACS
 document clinical outcomes following hospital admission for ACS
 provide a new audit baseline whereby necessary evidence-based
changes can be planned, and against which future changes can be
measured
 examine the psychological well-being (levels of depression) of
patients during their hospital admission
 provide confidential feedback to participating centres regarding their
level of adherence to  guidelines and also allow comparison  with the
national findings.
1.3 Acute coronary syndromes (ACS)
1.3.1 Acute coronary syndromes (ACS)
For the present survey, it was decided to extend the range of patients assessed
from suspected AMI (as was the case in previous censuses) to all ACS patients
as some treatments for other ACS (e.g. unstable angina) can be similar to
treatment for AMI, depending on the severity of the event13 (e.g. angioplasty
treatment for unstable angina). The present survey included patients with
suspected other ACS admitted to I/CCU in order to assess the care received by
those patients.
ACS includes both unstable angina and both persistent-ST-segment elevation
and non-ST segment elevation AMI.14-16 The definitions of the Consensus
Statement of the Joint European Society of Cardiology/American College of
Cardiology Committee, 200016 were adopted (further details available in section
2.1.3 and Appendix A).
4Changes in the definition of AMI in recent years have lead to an increase in the
proportion of diagnosed AMI patients and a decrease in the proportion of patients
diagnosed as having unstable angina.17-19 These changes preclude an exact
comparison with the findings of the 1994 census8, but the present survey
incorporated the prior definition and included the measurement of troponin levels
as defined by the Consensus statement of the Joint European Society of
Cardiology/American College of Cardiology Committee (2000)16 (see section
2.1.3 and Appendix A).
1.4 Treatment for AMI
1.4.1 Thrombolysis
Thrombus formation is the primary reason for myocardial infarction.20 This
usually occurs after a complex interaction between coronary atherosclerosis,
plaque rupture and platelet activation. Thrombolysis is an appropriate treatment
for myocardial thrombus formation, and when delivered in a ‘timely’ manner,
preferably within 6 hours of symptom onset21, but up to 12 hours after symptom
onset21 22, can significantly reduce morbidity and mortality from AMI. Each hour of
time saved can lead to a decrease of about 1.6 deaths per 1000 patients
treated.22
Since earlier administration of thrombolysis improves prognosis23, various
systems have been proposed to speed its delivery.  These include administration
of thrombolysis by specially trained emergency medical technician (EMT) staff in
a pre-hospital setting24; by staff in the Emergency Department5; and by specially
trained nurses in the CCU which bypass assessment by the medical team in the
Emergency Department.25 26 Also, pre-hospital recording and interpreting of
ECGs to diagnose AMI can markedly reduce the time delay between arrival at
hospital and starting thrombolysis.27
Inappropriate administration of thrombolysis raises subsequent mortality rates.22
Concerns about Emergency Department thrombolysis, such as failure to receive
thrombolysis when eligible, or increases in inappropriate administration of
thrombolysis28 29 have largely been outweighed by the significant reductions in
‘door-to-needle’ times which Emergency Department thrombolysis has managed
5to achieve.30 31 A meta-analysis has shown that pre-hospital thrombolysis
reduced treatment times.32 Other international research has shown that
community thrombolysis reduced pain to needle times and is a feasible option.33
A similar initiative recently conducted in Ireland in the North Western Health
Board, with GP initiated thrombolysis, also showed a reduction in pain to needle
time.34 Other factors can also affect treatment time, e.g. patients who arrived by
ambulance were found to have been treated more quickly than those who arrived
by other means.35
1.4.2 Percutaneous Coronary Interventions
Larger hospitals now have the facilities and expertise to use percutaneous
coronary interventions (PCI) instead of thrombolysis for treatment of AMI. This
treatment is increasingly used in the Irish setting, and its current status will be
assessed in this report.
1.5 Post-infarct depression
1.5.1 Depression after AMI
Post-AMI morbidity and mortality have been shown to be affected by a number of
independent risk factors, including extent of coronary artery disease, infarct size,
severity of left ventricular dysfunction, but also depression.12 36-40 Depression was
also found to be an important risk factor in further coronary events41, with even
low levels of depression having a significant effect on risk of mortality.42
As depression is an independent risk factor for mortality, the extent of depression
in post-AMI patients is a concern for clinicians. A recent review found that
between 8% to 45% of patients who have suffered an AMI exhibit symptoms of
major depression.39 Therefore, early diagnosis and active management of
depression is crucial to treating cardiac-related morbidity and mortality.43
The mechanisms by which depression is an independent risk factor for post-AMI
mortality are not fully understood.44 One important factor is that patients with
depression are less likely to adhere to recommendations for secondary
prevention to reduce cardiac risk.45 46 A recent meta-analysis showed that non-
adherence to medical treatment is three times more likely to occur with
depressed than non-depressed patients.47
6Because of its independent contribution to mortality, it was decided to assess
depression in this survey.  Assessment methods for depression have traditionally
involved clinical interviews with experienced mental health professionals or
lengthy self-completion questionnaires. Some brief screening instruments exist
but these have not been tested for their relative sensitivity in the cardiac setting.
The large sample size in this study provided an opportunity to compare two of the
most popular short-form self-completion depression scales, the Hospital Anxiety
and Depression Scales48-50 and the Beck Depression Inventory - Fast Scale51 52
(outlined in Chapter 2).
1.6 The present study
The present survey assessed the current hospital treatment of suspected ACS
patients nationally. The survey was necessary to ascertain the extent of
improvements in treatment times and adherence to new guidelines on treatment.
It aims to provide a benchmark of data to implement time-saving (and life-saving)
strategies nationally and in individual centres. The survey focuses on risk factors,
dates and times of the onset of symptoms and receipt of treatments, aspects of
patients’ admission, treatments received and the eventual discharge details of
suspected ACS patients. It also, for the first time in Ireland, assessed the
psychological (depression) status of ACS patients in the in-hospital phase after
their acute event, and compared the merits of two short-form self-report scales,
the Hospital Anxiety and Depression Scales48-50 and the Beck Depression
Inventory - Fast Scale.51 52
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Method
2.1 Sample/Participants
2.1.1 Hospitals
As with previous surveys, all centres in Ireland that admit suspected AMI patients
to coronary care units (CCUs) or intensive care units (ICUs) were invited and
agreed to participate in the survey (N=39).
2.1.2 Participants
Data collection started nationally on January 20th 2003 in 35 centres. Data
collection in 4 centres was delayed due to administrative difficulties. Data
collection started in these centres on 31st March 2003 (3 centres), and 14th April
2003 (1 remaining centre). Participating hospitals recruited all consecutive
suspected ACS patients, until 25 suspected cases of AMI (to match the criteria
for previous censuses) had been admitted to I/CCU. Data collection stopped in
the centres when the 25th suspected AMI patient was recruited (although some
centres provided extra AMI cases). A total of 1356 participants were recruited for
this survey. A cut-off date was used (24th Oct 2003), by which time 4 hospitals
had not recruited 25 suspected AMI patients (none of these hospitals started
later than January 20th 2003).
2.1.3 Definitions used
Inclusion Criteria: Suspected Acute Coronary Syndrome (ACS) patients admitted
to I/CCU. This included patients with an admission diagnosis of either acute
myocardial infarction or unstable angina. The following standard definition of
ACS was provided to all physicians and data collectors during training for the
study.
Definition of ACS (Consensus statement of the Joint European Society of
Cardiology/American College of Cardiology Committee, 2000):16 ACS includes
cardiac events referred to as unstable angina, non-ST-segment-elevation
myocardial infarction (MI) and ST-segment-elevation MI.
8The definition of acute coronary syndrome included patients presenting with
ischaemic cardiac chest pain in the following categories:
(a) unstable angina
(b) non Q wave MI
(c) AMI with ST segment elevation and Q wave development
(d) patients who experience abrupt closure of a coronary artery during
percutaneous coronary interventions.
Definition of Acute Myocardial Infarction (AMI)16: Criteria for acute, evolving or
recent MI: either one of the following:
(1) Typical rise and gradual fall  (troponin) or more rapid rise and fall (CK-MB) of
biochemical markers of myocardial necrosis with at least one of the following:
(a) ischaemic symptoms
(b) development of pathologic Q waves on the ECG
(c) ECG changes indicative of ischaemia (ST segment elevation or
depression) or
(d) coronary artery intervention (e.g. coronary angioplasty)
(2) Pathologic findings of an acute MI.
Further information on these definitions is set out in Appendix A.
2.2 Measures
2.2.1 Survey Form
The full survey form can be viewed in Appendix B. As the present survey was a
follow-up of the 1994 census8, the same variables were used with some
adjustments to incorporate contemporary cardiological practices. The form
assessed the following areas: demographic and past clinical history, risk factors,
dates and times from symptom onset to hospital discharge, admission details,
acute treatments given and discharge status.
2.2.2 Depression self-report measures
a) Beck Depression Inventory – Fast Scale (BDI-FS)
Nineteen hospitals were allocated the 7-item Beck Depression Inventory Fast
Scale (BDI-FS). The BDI-FS is a screening instrument that minimises the
possibility of yielding spuriously high estimates of depression for patients with
9medical problems by focusing on cognitive (as distinct from physical) symptoms
such as sadness, pessimism, past failure, loss of pleasure (anhedonia), self-
dislike, self-criticalness and suicidal thoughts or wishes. Each item has a four
answer option format. Scores ranging from 3 for most severe to 0 for absence of
problem in that area. This shortened version of the widely used Beck Depression
Inventory (BDI)53 was developed to aid the family physician in estimating the
severity of depression in patients. Psychometric evidence suggests that the two
versions are highly correlated and both have approximately the same high
internal reliability.52 54
Studies have consistently found that a BDI-FS cut-off score of ≥4 yields a
sensitivity rate of >90% for detecting major depressive disorders in adolescents
and adults seeking routine medical evaluations by primary care physicians.55 56 In
these studies, specificity rates (to exclude patients who do not have major
depressive disorder) have been >0.85. The ≥4 cut-off in the BDI-FS has also
been shown to be suitable for geriatric outpatient populations.57
The present study utilised a cut-off score of ≥4 to indicate depression in patients
admitted to I/CCU with suspected ACS.
b) Hospital Anxiety and Depression Scale (HADS)
Nineteen hospitals were allocated the 14-item Hospital Anxiety and Depression
Scales (HADS). One hospital which was originally randomly assigned the HADS
did not participate in this part of the survey. The HADS consists of a 7-item
depression scale (HADS-D) and a 7-item anxiety scale (HADS-A).48 49  Each item
had a four answer option format. Scores range from 3 for most severe to 0 for
absence of problem in that area.
The HADS was developed to identify psychological disturbances in general
medical and non-psychiatric samples. As a screening instrument, it can indicate
probable cases of anxiety or depression. However, more detailed clinical
interviews are necessary to make definitive diagnoses.
Interpretation of the HADS is based primarily on the use of cut-off scores,
although there is no single, generally accepted cut-off score.58 The authors
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recommended that, for the Anxiety and Depression scales alike, raw scores of
≥11 are used to indicate probable depression or anxiety, with scores of 8-10
necessitating further investigation. However, several subsequent studies have
suggested that the optimal cut-off score is ≥8 for both the depression and anxiety
subscales59, with Roberts and colleagues60 finding a cut-off of ≥8 is appropriate
for female cardiac patients.
The present study uses a cut-off of ≥11 in the HADS-D scale to identify probable
cases of depression and ≥8 to identify cases requiring further investigation, in
line with previous research on cardiac patients.
2.3 Procedure
2.3.1 Ethical approval and hospital participation
The survey was submitted to the Royal College of Surgeons in Ireland’s
Research Ethics Committee and to all relevant regional and hospital research
ethics committees (a total of 17 committees). Following approval, all consultants
in the 39 hospitals were written to requesting permission to include their patients
in the survey (see Appendix C for the consultant information letter and consent
form).
2.3.2 Data collection
Local data collectors were trained by the research officer at one of 3 locations
nationally. Appropriate patients (suspected ACS and admitted to I/CCU) were
identified by the data collectors, and approached to participate in the survey (the
patient information sheet and consent forms are available in Appendices D and E
respectively). Patients were generally approached for consent 2-5 days after
admission to I/CCU for suspected ACS. When written permission was obtained,
the data collector collected information from patients which would not usually be
included in the patient charts. Hospitals were randomly assigned the BDI-FS or
the HADS. The data collector also gave the patient the allocated depression
questionnaire and an envelope, and asked the patient to complete this and return
it to him/her in a sealed envelope. The completed questionnaire was then
forwarded to the research officer. When the patient was discharged, the data
collector completed the audit form from the hospital records and forwarded the
form to the research officer (by post or fax).
11
Chapter 3
Results
3.1 Demographic profile
3.1.1 Participants Demographic Profile
Of the 1365 suspected ACS participants (i.e. suspected AMI and suspected other
ACS), 979 (72%) were men, 386 (28%) were women. The mean age was 64.4
years (std dev=13.3; median=65.3; range=20-100yrs). Mean age for men was
62.6 years (std dev=12.9; median=63; range=20-100). Mean age for women on
I/CCU admission of 69 years (std dev=13.3, median=71.2, range 23-94) was
significantly greater than that of men (X2=46.65; df=1; p<.0001).
Median distance from hospital at onset of symptoms was 8 miles. Suspected AMI
patients were a median of 9 miles from hospital at symptom onset, with
suspected other ACS patients a median of 8 miles away.
Admission characteristics are compared to the 1994 census in table 3.1.
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Table 3.1: Comparative demographic and admission profile in 1994 and 2003
CCU 2003 SurveyDemographic 1994
Census
(N=950
suspected
AMI)
Suspected
AMI
(N=935)
Suspected
Other ACS
(N=430)
Combined
(N=1365)
Sex (%)
Male
Female
68
32
70
30
75
25
72
28
Age (years) (mean) (std dev)
Male
Female
64 (12)
69 (11)
66 (13)
64 (13)
71 (13)
61 (14)
60 (13)
64 (14)
64  (13)
63 (13)
69 (13)
Referral source (%)
GP
Self
Other
69
24
7
53
39
8
54
33
12
53
37
9
Admission mode to hospital (%)
Ambulance
Car (Passenger)
Car (Driver)
Other
46
42
8
4
48
41
6
2
37
43
12
3
44
41
8
2
Distance from hospital at symptom onset
Median (range) 9 (0-165) 9 (0-80) 8 (0-150) 8 (0-150)
Previous CHD history (%)
AMI
Unstable angina
CABG
PTCA
24
14
4
2
16
14
5
6
31
28
13
18
21
19
7
10
There are two characteristics of note that have changed in the current sample.
Firstly, for suspected AMI patients, there has been a 16% decrease in GP
referrals, and a corresponding 15% increase in self-referred patients. Secondly,
there has been an increase of 4% in the numbers of suspected AMI patients who
had previously undergone a PTCA procedure. Also, suspected other ACS
patients have a greater prevalence of past CHD history than suspected AMI
patients.
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3.1.2   Annual through-put of suspected ACS patients admitted to I/CCU in
Ireland
Although thirty-nine hospitals participated in this survey, and their individual
through-puts vary considerably, the through-put of suspected ACS patients
admitted to I/CCUs in Ireland can be estimated by counting the number of
patients admitted to all 39 I/CCUs in the first 4 weeks of participation in the
survey, and multiplying this by 13 to give a 52 week picture. This gives an
estimate of 6331 suspected ACS patients who are admitted to I/CCU per annum
in Ireland. For suspected AMI patients, the estimated total admitted to I/CCU is
3783.
3.1.3 Employment, insurance status and urban/rural profiles
The employment profile of the current sample is displayed in table 3.2.
Table 3.2:  Employment profile of suspected ACS patients
Employment % Men
(N=979)
% Women
(N=386)
% Total
(N=1365)
Full-time 37 9 29
Part-time 5 5 5
Unemployed 6 2 5
Home duties <1 33 9
Disability benefit 4 2 3
Retired 47 48 47
Unknown/Other <1 <1 1
The majority of patients were retirees, though a substantial number of men were
still in full-time employment. Although 33% of women listed themselves with an
occupation of ‘home duties’, more than half of these patients were over 65 years
of age. Overall, two-thirds (66%) of the women in the current sample were aged
65 and over.
Health insurance status is displayed in table 3.3.
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Table 3.3: Health insurance status of patients admitted to I/CCU with suspected
ACS
Health Insurance % Men % Women % Total
General Medical Services 46 62 50
VHI/BUPA 29 25 28
Employer’s insurance 3 2 3
Unknown 3 1 2
Other 1 <1 1
None 19 10 16
Half of the admitted sample (50%) had general medical services (GMS) health
care cover. Patients over 70 years of age automatically qualify for GMS health
coverage. When those under age 70 years were considered separately, 38% had
GMS cover.
3.2 Cardiovascular risk factors
3.2.1 Smoking
The smoking status of the current sample is displayed in table 3.4.
Table 3.4: Smoking status of patients admitted to I/CCU by inclusion criteria
Smoking status  Suspected
AMI %
Suspected
Other ACS %
Total %
Current/(ex <6months) 39 34 38
Ex (≥6 months) 32 39 34
Never 28 26 27
Unknown 1 1 1
Seventy-two per cent of patients admitted to I/CCU for suspected ACS were
current smokers or ex-smokers.
3.2.2 Previous CHD History
Many patients have had a previous experience of CHD. The levels of previous
CHD history are shown in table 3.5.
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Table 3.5: I/CCU admissions for suspected ACS – Previous CHD history (some
patients will have had more than one previous risk indicator)
Past CHD History  Suspected
AMI %
Suspected
Other ACS %
Total
%
None 64 40 57
MI 16 31 21
Angina pectoris 14 29 19
Recent onset angina (<1 month) 3 8 4
Atrial fibrillation 2 1 2
Other 5 5 5
Unknown <1 <1 <1
Patients admitted for suspected other ACS had a higher prevalence of past CHD
history (60%) than those admitted for suspected AMI (36%). AMI was a first
acute coronary event for the majority of admitted suspected AMI patients.
Data on hypertension levels in the sample are illustrated in table 3.6.
Table 3.6: Past treatment for hypertension (patients may be on more than one
form of treatment)
Past hypertension history  Suspected
AMI %
Suspected Other
ACS %
Total %
No history of hypertension 61 57 60
History of hypertension
On treatment
-On drug treatment
-Diet
-Exercise
Untreated hypertension
39
34
33
6
3
5
43
39
37
8
6
4
40
35
34
6
4
5
Many patients (40%) admitted for suspected ACS had a prior history of
hypertension: 35% of the patients were on one or more forms of treatment. The
remaining 5% had a past history but were not listed as being on any form of
treatment for hypertension.
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3.2.3 Lipid profile
The lipid profiles of most patients admitted were assessed. Eighty-eight per cent
of patients admitted had their total cholesterol levels recorded. In order of usage
of test, hospitals recorded total cholesterol, triglycerides (83% of patients tested),
HDL (53%) and LDL (51%) cholesterol (Table 3.7).
Table 3.7: Lipid profile of patients admitted to I/CCU by admission criteria
Cholesterol (mmol/l)  Suspected
AMI %
Suspected
Other ACS %
Total %
Total cholesterol (N=1205)
Desirable (<5.17)
Borderline (5.17-6.18)
High (>6.18)
58
28
14
67
23
10
61
27
12
Triglycerides (N=1130)
Normal (0.8-2.0)
<0.8
High (>2.0)
62
12
26
59
10
31
61
12
28
HDL (N=727)
Desirable (>1.56)
Acceptable (1.04-1.56)
Low (<1.04)
15
49
36
14
46
39
15
48
37
LDL (N=690)
Optimal (<2.6)
Above/near optimal (2.6-3.35)
Borderline high (3.36-4.11)
High (4.12-4.89)
Very high (>4.90)
34
29
22
10
4
37
35
16
8
3
35
31
21
9
4
The majority of patients in the current sample were within currently accepted
parameters for cholesterol levels. The least satisfactory profile was for HDL
(‘good’) cholesterol, with only 15% in the ‘desirable’ bracket. However, a further
48% were within the ‘acceptable’ bracket.
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The summary scores of the above lipid profiles are shown in table 3.8.
Table 3.8: Summary scores of the lipid profile of patients admitted to I/CCU by
admission criteria
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The possible interactions between cholesterol levels and previous history of ACS
(unstable angina or MI) were investigated. Patients with a positive history of ACS
had significantly lower total cholesterol (median 4.6 vs. 4.9 mmol/l; p<.0001) and
LDL levels (median 2.7 v 3.1 mmol/l; p<.0001), but no differences were seen for
triglyceride and HDL cholesterol levels. This finding may be accounted for by
past statin prescription post-ACS episode. Patients who were on statin therapy
prior to the current admission had lower total cholesterol (median 4.3 vs. 5.0
mmol/l; p<.0001) and LDL levels (median 2.4 vs. 3.1 mmol/l; p<.0001) than
patients who were not taking statins, with no differences for triglyceride and HDL
cholesterol levels.
3.2.4 Previous cardiovascular medications
A substantial minority (43%) of patients had already had some form of CHD (see
table 3.5), and some patients had a history of hypertension (40%) (table 3.6).
Overall, 62% of the sample were already prescribed cardiovascular medication.
The profile of cardiovascular medication used is presented in table 3.9.
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Table 3.9: Proportion of total sample on prior cardiovascular medication by
inclusion criteria
Cardiovascular Medication  Suspected
AMI %
Suspected
Other ACS %
Total %
Aspirin 32 54 39
Other anti-platelet 6 16 9
Beta-blocker 22 36 26
Alpha-blocker 1 2 1
ACE inhibitor 20 34 24
Calcium antagonist 8 8 8
Statin 20 41 27
Nitrate 8 22 13
Diuretic 8 8 8
Anticoagulant 1 2 2
Glycoside 2 3 3
Potassium channel opener 1 3 2
Anti-arrythmic 1 2 1
Anti-anginal 1 2 1
Other* 2 4 2
* Angiotensin II antagonist, alpha agonist, unspecified anti-hypertensive
These results can be compared to patients with a previous history of ACS (MI
and unstable angina). Table 3.10 shows the medication regimens of patients who
had a history of ACS prior to the current admission.
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Table 3.10: Proportion of sample with positive history of ACS on prior
cardiovascular medication by inclusion criteria
Cardiovascular Medication  Suspected
AMI %
Suspected
Other ACS %
Total %
Aspirin 72 79 75
Other anti-platelet 14 27 20
Beta-blocker 45 53 49
Alpha-blocker 1 3 2
ACE inhibitor 38 46 42
Calcium antagonist 14 11 12
Statin 47 61 53
Nitrate 24 35 29
Diuretic 15 11 13
Anticoagulant 3 3 3
Glycoside 4 3 4
Potassium channel opener 3 5 4
Anti-arrythmic 1 2 1
Anti-anginal 3 3 3
Other* 1 5 3
* Angiotensin II antagonist, alpha agonist, unspecified anti-hypertensive
The most common cardiac medications for patients with a previous ACS history
were aspirin (75%), statins (53%), beta-blockers (49%) and ACE inhibitors
(42%). Seventy-eight per cent of patients with a past ACS history were
prescribed either aspirin or other anti-platelet medication.
3.2.5 Immediate Family CHD History
Family history of CHD in the sample was also assessed. Patients were asked if
they had an immediate relative (mother, father, brother, sister) who had CHD
before the age of 55 years for males and 65 years for females. This data was
only available for 1229 patients. Of this 1229, 44% had a positive family history
for CHD. This divided into 42% of suspected AMI patients, and 47% of suspected
other ACS patients having a positive family CHD history. A similar level of
positive family CHD history was seen for both males and females (44%).
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3.2.6 History of Diabetes
Prevalence of pre-hospitalisation diabetes is shown in table 3.11.
Table 3.11: Pre-admission diagnosed diabetes by inclusion criteria
Diabetes pre
I/CCU admission
 Suspected
AMI %
Suspected
Other ACS %
Total %
None 84 86 85
IDDM (Type I) 4 4 4
NIDDM (Type II) 11 10 11
Unknown 1 <1 <1
The figures in table 3.11 do not include patients who were diagnosed with
diabetes during or after this admission for suspected ACS (data on diagnoses of
diabetes during admission was not collected).
3.2.7 Coronary Interventions prior to current admission
Coronary interventions that patients received prior to the current hospitalisation
are shown in table 3.12.
Table 3.12: Coronary interventions prior to admission by inclusion criteria
(patients may have had more than one intervention)
Coronary
Interventions
 Suspected
AMI %
Suspected
Other ACS %
Total %
None 88 70 83
PTCA 3 6 4
PTCA and Stent 3 12 6
CABG 5 13 7
Other 1 2 1
3.3 Time to Treatment
3.3.1 Overall time to treatment
Time to treatment is crucial in the treatment of ACS. Time to treatment can be
divided into several points: symptom onset, call for professional help, hospital
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arrival, I/CCU admission, administration of thrombolysis or direct angioplasty (if
received). The median times to treatment for different stages of ACS and AMI are
illustrated in the following section, and where possible the data is compared to
the 1994 census. The changes in practice for patients who received thrombolysis
are illustrated in Figure 3.1.
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Figure 3.1: Thrombolysis administration locations and treatment times in 1994
and 2003
Both place and speed of administration of thrombolysis have changed
considerably in a positive direction since 1994. Progress has been made for
patients who are thrombolysed, with thrombolysis delivered in the Emergency
Department occurring at a significantly shorter time (median 35 minutes) than
CCU administered thrombolysis (median 60 minutes) in the current sample
(z=5.582, p<.001).
Overall time to treatment is presented in table 3.13. As in the 1994 census, total
time to treatment is defined as symptom onset to thrombolysis or direct PTCA, or
symptom onset to I/CCU admission if the patient did not receive one of these
treatments.
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Table 3.13: Median overall time to treatment for all patients
CCU 2003 SurveyTreatment times 1994 Census
(N= 950
suspected
AMI patients)
(median)
 Suspected
AMI (N=935)
(median)
Suspected
Other ACS
(N=430)
(median)
Total
(N=1365)
(median)
Symptom onset to hospital 3h 30mins 3h 35mins 4h 39mins 3h 57mins
Hospital arrival to I/CCU 55mins 1h 41mins 2h 40mins 1h 56mins
Hospital arrival to thrombolysis 76mins 45mins ‡ ‡
CCU admission to thrombolysis 25mins 20mins ‡ ‡
Total ‡‡ 4h 30mins 6h 00mins 10h 19mins 7h 15mins
Inpatient and other hospital transfer times not included in the analysis for 1994 or 2003 samples.
Mobile CCU arrival time is defined as hospital arrival time where relevant
‡Only 2 patients admitted for suspected other ACS were later thrombolysed, and this occurred
36hrs and 67h 15mins after admission respectively. These times are excluded from time
calculations here
‡‡Total is defined as symptom onset to thrombolysis or direct PTCA, or symptom onset to I/CCU
admission if the patient did not receive one of these treatments
Suspected AMI patients waited a similar length of time to get to hospital from
onset of symptoms in 2003 as 1994 (median 3h 39mins v 3h 30mins). This figure
was substantially higher for patients admitted with suspected other ACS, who
waited a further 1h 21 minutes from symptom onset to hospital arrival (a
significantly longer wait, z=-2.86; p<.01).
Patients waited longer in 2003 to be admitted to I/CCU (46 minutes longer for
suspected AMI patients), but received thrombolysis more quickly, i.e. 45 minutes
after hospital arrival (compared with 76 minutes in 1994). Both these findings are
unsurprising, as more thrombolysis now occurs in the Emergency Departments
(see table 3.24 later). The hospital arrival to thrombolysis time of 45 minutes
represents a 41% decrease in time to treatment since 1994.
It is recommended that patients should receive thrombolysis within 90 minutes of
calling for professional help (emergency services or GP), and within 30 minutes
of arrival at the Emergency Department.2 4 6 The present survey found that 29%
of patients were thrombolysed within 90 minutes of calling for professional help.
Forty-two percent of patients were thrombolysed within 2 hours, and 62% were
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thrombolysed within 3 hours of calling for professional help. On arrival at hospital,
35% of patients were thrombolysed within 30 minutes. Sixty percent of patients
were thrombolysed within 60 minutes, and 74% were thrombolysed within 90
minutes of arriving at the Emergency Department.
Total time to treatment is defined as symptom onset to thrombolysis or direct
PTCA, or symptom onset to I/CCU admission if the patient did not receive one of
these treatments. Suspected other ACS in 2003 patients waited 5h 49mins
longer than suspected AMI patients in 1994. Suspected other ACS patients also
waited 4h 14mins longer than suspected AMI patients in 2003 (a significant
difference, z=-6.471, p<.001). A longer delay in total time to treatment was seen
in 2003 compared with 1994, with suspected AMI patients now waiting 1h 35
minutes longer to receive treatment overall. The cause of this delay is
investigated in table 3.14.
Table 3.14: Differences in median time to treatment for thrombolysed and non-
thrombolysed suspected AMI patients in 2003
Treatment times Suspected AMI
-thrombolysis
received
(median)
Suspected AMI
-did not receive
thrombolysis
(median)
Symptom onset to hospital 2h 35mins 5h 00mins***
Hospital arrival to I/CCU 1h 10mins 2h 15mins***
Total ‡‡ 4h 00mins 10h 00mins***
Inpatient and other hospital transfer times not included in the analysis. Mobile CCU arrival time
is defined as hospital arrival time where relevant
‡‡Total is defined as symptom onset to thrombolysis or direct PTCA, or symptom onset to I/CCU
admission if the patient did not receive one of these treatments
 (Mann Whitney U test, *p<.05, **p<.01, ***p<.001)
This extended total delay time seen for suspected AMI patients in table 3.13 is
largely due to suspected AMI patients who are not receiving thrombolysis.
Suspected AMI patients who are subsequently thrombolysed present to hospital
and are treated significantly more quickly than suspected AMI patients who are
not thrombolysed. Suspected AMI patients who are not thrombolysed have
similar treatment times to suspected other ACS patients as listed in table 3.13.
25
There was no significant difference in total time to treatment between suspected
other ACS patients and suspected AMI patients who were not thrombolysed, but
suspected AMI patients who did not receive thrombolysis were admitted to I/CCU
significantly faster (median 2h 15mins) than patients admitted with suspected
other ACS (median 2h 40mins)(z=2.128, p<.05).
The data for the current survey is compared to some previous Irish data in table
3.15.
Table 3.15: A comparison of time to treatment for AMI from previous Irish
studies
Year Pre-
hospital
delay time
Call to
thrombolysis
time
Hospital
admission to
thrombolysis
time
%
thrombolysed
MacGowan et al
(1991)
‘85-
‘87
7h 54mins 6h 00mins - 58
O’Callaghan et al
(1995)
‘92 6h (Dublin)
4h (Other)
- - 35
McGee et al (1996) ‘94 3h 30mins - 1h 16mins 58
O’Neill et al (2003) ’99-
‘01
- 3h 20mins - 31
CCU 2003 ‘03 3h 35mins 2h 25mins 45mins 43
There has been little time to treatment change in the pre-hospital phase since
1994. A fall in the percentage of confirmed AMI patients who were thrombolysed
in 2003 compared to 1994 was noted. This will be discussed later.
The cumulative percentages of confirmed AMI patients who present to hospital
by hour after symptom onset is illustrated in Figure 3.2.
26
0
10
20
30
40
50
60
70
80
90
100
1
h
r
2
h
rs
3
h
rs
4
h
rs
5
h
rs
6
h
rs
7
h
rs
8
h
rs
9
h
rs
1
0
h
rs
>
1
0
h
rs
Symptom onset to hospital presentation (hours)
C
u
m
u
la
ti
v
e
 %
Other ACS 2003 AMI 2003 Total sample 2003 AMI 1994
Figure 3.2: Proportion of patients arriving at hospital per hour from symptom
onset for current sample (suspected other ACS, suspected AMI,
Total) and 1994 data (suspected AMI)
The presentation pattern of patients in the current sample appears quite similar
to the pattern seen in 1994. Differences in presentation pattern for the current
sample of confirmed AMI patients who were thrombolysed and those who did not
receive thrombolysis are presented by inclusion criteria in Figure 3.3.
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Figure 3.3: Proportion of patients arriving at hospital per hour from symptom
onset for current sample (suspected other ACS, suspected AMI – not
thrombolysed, suspected AMI – thrombolysed)
Figure 3.3 illustrates how suspected AMI patients who were later thrombolysed
presented to hospital significantly more rapidly than both suspected AMI patients
who were not thrombolysed and suspected other ACS patients. Indeed, 77% of
patients who received thrombolysis received it within the optimal time of 6 hours
after symptom onset.21 It is also clear that suspected AMI patients who did not
subsequently receive thrombolysis had a similar time to presentation pattern to
patients who presented with suspected other ACS.
3.3.2 ‘Snapshot’ of time to ACS treatment in Ireland
To determine the national ‘snapshot’ of time to ACS treatment, data on all
patients admitted up to 42 days after the start date (42 days was the length of
time it took the first hospital to recruit their 25th suspected AMI) were analysed.
Data for this cohort are seen in table 3.16.
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Table 3.16: A ‘snapshot’ of suspected ACS patients nationally
CCU 2003 SurveyTreatment times
Suspected
AMI (447)
(median)
Suspected
Other ACS
(259)
(median)
Combined
(706)
(median)
Symptom onset to hospital 3h 35mins 4h 39mins 3h 50mins
Hospital arrival to I/CCU 2h 00mins 3h 00mins 2h 14mins
Hospital admission to thrombolysis 45mins - -
Total‡‡ 6h 30mins 10h 25mins 7h 33mins
Inpatient and other hospital transfer times not included in the analysis for 1994 or 2003 samples.
Mobile CCU arrival time is defined as hospital arrival time where relevant
‡‡Total is defined as symptom onset to thrombolysis or direct PTCA, or symptom onset to I/CCU
admission if the patient did not receive one of these treatments
The data in table 3.16 are strikingly similar to the data presented in table 3.13.
The ‘snapshot’ data reflects the care patients normally receive nationally,
whereas data in table 3.13 over-represents hospitals which have fewer
admissions annually. This suggests that there is little difference in time to
treatment for patients attending more or less busy hospitals, in terms of ACS
admissions nationally.
3.3.3 Confirmed AMI patients and time to treatment
Not all patients admitted were subsequently confirmed as ACS patients. Time to
treatment for patients subsequently confirmed as having had an AMI is presented
in table 3.17.
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Table 3.17: Median time to treatment for confirmed AMI patients
CCU 2003 SurveyTreatment times 1994 Census
(620 confirmed
AMI patients)
Suspected
AMI (846
confirmed
AMI)
(median)
Suspected
Other ACS
(82
confirmed
AMI)
(median)
Combined
(928
confirmed
AMI)
(median)
Symptom onset to hospital 3h 00mins 3h 35mins 5h 47mins 3h 45mins
Hospital arrival to I/CCU 50mins 1h 37mins 3h 05mins 1h 43mins
Hospital (or I/CCU)
admission to thrombolysis
25mins 45mins ‡ ‡
Total‡‡ 4h 09mins 5h 55mins 12h 23mins 6h 27mins
Inpatient and other hospital transfer times not included in the analysis for 1994 or 2003 samples
‡Only 2 patients admitted for suspected ACS were later thrombolysed, and this occurred 36hrs
and 67h 15mins after admission respectively.
1994 median hospital arrival to thrombolysis is defined as I/CCU admission to thrombolysis
time, as 96% of thrombolysis occurred in I/CCU in 1994  (table 3.24)
‡‡Total is defined as symptom onset to thrombolysis or direct PTCA, or symptom onset to I/CCU
admission if the patient did not receive one of these treatments
An increase in the percentage of confirmed AMI patients is seen in 2003
compared with 1994; in 1994, 70% of suspected AMI patients were later
confirmed as having had an AMI, compared to 91% in 2003 (see table 3.26
later).
In 1994, confirmed AMI patients presented to hospital a median of 3 hours after
symptom onset, compared with 3 hours 30mins (see table 3.13) for the overall
sample (a significant difference). In contrast, no significant difference was seen
for confirmed AMI patients compared to time to treatment for the suspected AMI
group (z=0.6202, p>0.5). The finding for the current suspected AMI patients was
similar in the suspected other ACS group – those later confirmed as having had
an AMI did not present more quickly than the rest of the sample (z=-0.6094,
p>.05).
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Interestingly, for patients who were subsequently confirmed as having had an
AMI, patients presenting as suspected other ACS presented to hospital more
slowly than those presenting as suspected AMI (1.961, p<.05).
3.3.4 GP referrals and time to treatment
The 1994 census found that GP-referred patient treatment times were
significantly longer than those who self-referred. The relationship of referral route
(self v GP referred) to time to treatment in the current sample is investigated in
table 3.18.
Table 3.18: Time to treatment for AMI and other ACS by referral route
1994 Census
(suspected AMI)
CCU 2003 Survey
(suspected AMI)
Treatment times
Self-referral
(N=228)
GP referral
(N=655)
Self-referral
(N=360)
GP referral
(N=489)
Symptom onset to hospital 2h 05mins 4h 15mins*** 2h 28mins 5h 03mins***
Hospital arrival to I/CCU 60mins 50mins*** 1h 40mins 1h 44mins
Hospital (or I/CCU) admission
to thrombolysis
24mins 25mins 45mins 45mins
Total‡‡ 3h 10mins 5h 00mins*** 4h 45mins 7h 30mins***
CCU 2003 Survey
(suspected other ACS)
CCU 2003 Survey
(combined AMI and other
ACS)
Self-referral
(N=141)
GP referral
(N=232)
Self-referral
(N=335)
GP referral
(N=423)
Symptom onset to Hospital 2h 59mins 6h 02mins*** 2h 30mins 5h 20mins***
Hospital arrival to I/CCU 2h 47mins 2h 25mins** 2h 00mins 1h 52mins**
Hospital arrival to thrombolysis - - 45mins 45mins
Total‡‡ 9h 50mins 10h 15mins 5h 30mins 8h 30mins***
(Mann Whitney U test, *p<.05, **p<.01, ***p<.001)
1994 median hospital arrival to thrombolysis is defined as I/CCU admission to thrombolysis time,
as 96% of thrombolysis occurred in I/CCU in 1994  (table 3.24)
‡‡Total is defined as symptom onset to thrombolysis or direct PTCA, or symptom onset to I/CCU
admission if the patient did not receive one of these treatments
Patients who self-referred had a significantly shorter time to treatment than those
who were referred by a GP. This is a similar finding to the 1994 data. The pattern
also occurs for those patients admitted for suspected other ACS.
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Differences in treatment and outcome characteristics between self-referral or GP
referred patients are explored in table 3.19.
Table 3.19: Prior CHD history and clinical outcomes by referral route (1994 and
2003)
1994 Census
(suspected AMI)
CCU 2003 Survey
(suspected AMI)
Self-referral
(N=228)
GP referral
(N=655)
Self-referral
(N=360)
GP referral
(N=489)
Previous CHD History (%)
AMI
Unstable angina
CABG/PTCA
28
12
11
22
14
4*
17
11
13
16
15
8*
Median distance from hospital 3 miles 12 miles*** 4 miles 14 miles***
Diagnosis (%)
AMI
Unstable angina
70
13
70
14
90
4
91
4
Mortality rate (%) 8 10 8 9
CCU 2003 Survey
(suspected other ACS)
CCU 2003 Survey
(combined AMI and other
ACS)
Self-referral
(N=141)
GP referral
(N=232)
Self-referral
(N=335)
GP referral
(N=423)
Previous CHD History (%)
AMI
Unstable angina
CABG/PTCA
37
29
30
26*
28
25
23
16
18
19
19
14*
Median distance from hospital 4 miles 12 miles*** 4 miles 14 miles***
Diagnosis (%)
AMI
Unstable angina
18
47
19
43
70
16
68
16
Mortality rate (%) 1 1 6 6
 (Mann Whitney U test, *p<.05, **p<.01, ***p<.001)
Patients were more likely to self-refer if they lived closer to the hospital for both
suspected AMI and suspected other ACS patients (this was also the case in
1994 for suspected AMI patients). Suspected AMI patients who had a previous
coronary intervention (PTCA or CABG) were also more likely to self-refer. This
was not the case for suspected other ACS patients.
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With the exception of greater self-referral in those who had a history of PTCA or
CABG, there was no difference in prior CHD history among suspected AMI
patients who self-referred and those who were referred by a GP. Thus prior
patient experiences with CHD did not appear to influence decisions to seek care.
Instead, in both surveys, those who self-referred lived nearer to the attending
hospital. There was a difference in CHD history for suspected other ACS
patients, with patients who previously experienced an AMI being more likely to
self-refer than go to a GP.
3.3.5 Previous experience of AMI
The effect of previous experience of AMI on times to treatment is illustrated in
table 3.20.
Table 3.20: Time to treatment and prior experience of AMI in (1994 and 2003)
1994 Census
(suspected AMI)
CCU 2003 Survey
(suspected AMI)
Treatment times
Previous AMI
(N=211)
No previous
AMI (N=739)
Previous AMI
(N=146)
No previous
AMI (N=780)
Symptom onset to hospital 3h 15mins 3h 55mins 3h 02mins 3h 45mins
Hospital arrival to I/CCU 60mins 55mins 1h 30mins 1h 43mins
Hospital arrival to thrombolysis§ 37mins 25mins 50mins 45mins
Total‡‡ 4h 28mins 4h 28mins 5h 30mins 6h 20mins
CCU 2003 Survey
(suspected other ACS)
CCU 2003 Survey
(combined AMI and other
ACS)
Previous AMI
(N=135)
No previous
AMI (N=295)
Previous AMI
(N=281)
No previous
AMI
(N=1075)
Symptom onset to hospital 3h 42mins 5h 17mins* 3h 09mins 4h 00mins
Hospital arrival to I/CCU 2h 05mins 2h 50mins 1h 50mins 2h 00mins
Hospital arrival to thrombolysis - - 50mins 45mins
Total‡‡ 8h 30mins 11h 55mins** 6h 40mins 7h 15mins
Inpatient and other hospital transfer times not included in the analysis for 1994 or 2003 samples
§1994 median hospital arrival to thrombolysis is defined as I/CCU admission to thrombolysis time,
as 96% of thrombolysis occurred in I/CCU in 1994  (table 3.24)
‡‡Total is defined as symptom onset to thrombolysis or direct PTCA, or symptom onset to I/CCU
admission if the patient did not receive one of these treatments
 (Mann Whitney U test, *p<.05, **p<.01, ***p<.001)
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For suspected AMI patients, a previous experience of having an AMI did not
make a difference to hospital presentation and treatment times. This reiterates
the findings of the 1994 census. The findings were different for those patients
admitted with suspected ACS. In these cases, patients with experience of
previous AMI presented to the hospital more quickly than those with no
experience of a previous AMI. They also had a faster total time to treatment.
3.3.6 Hospital stay
Patients admitted with a suspected AMI in 2003 stayed in I/CCU a median of 4
days, and stayed in another ward in the hospital a median of 3 days after I/CCU
discharge. The median total hospital stay after admission for suspected AMI was
8 days. Patients admitted with other suspected ACS stayed in I/CCU 3 days
(median), in another ward post I/CCU discharge 2 days (median), and had a total
hospital stay of 7 days (median). This compares with a hospital stay of 7-8 days
described in the Euro Heart Survey.15
3.4 Admission details
Patients can be referred to hospital by many sources. These are displayed in
table 3.21 for the current sample.
Table 3.21: Admission details to I/CCU by inclusion criteria
Referral Source  Suspected
AMI %
Suspected
Other ACS %
Total %
GP 53 54 53
Self 39 33 37
Friend/Family 2 1 2
OPD 1 3 2
Inpatient 2 3 2
Other Hospital 2 5 3
Both suspected other ACS and suspected AMI patients were referred to hospital
more often by GP than by self-referral route. These two routes are the main
forms of referral for suspected ACS patients.
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The mode of transport to hospital is assessed in table 3.22, and is examined by
different demographic details of the sample.
Table 3.22: Admission mode by demographic details
Admission
Mode
% AMI % Other
ACS
% Urban % Rural Self-
Referral
GP-
referred
Distance
from
Hospital-
miles
(median)
Ambulance 50 38*** 45 47 40 50** 10
Car (Self) 6 11*** 7 6 9 7 4
Car
(Passenger)
40 44 39 44 46 40* 8
Other 2 3 3 1 3 2 1
Data for inpatient and OPD transfers not included in analysis
(Mann Whitney U test, *p<.05, **p<.01, ***p<.001)
Patients were more likely to use an ambulance if they had a suspected AMI and
were referred by a GP. Conversely, they are more likely to drive themselves to
hospital if they had suspected ACS, and more likely to be driven to hospital if
they referred themselves.
Cardiac arrest was reported in 6% of the patients admitted in 2003 (8%
suspected AMI patients and 1% suspected other ACS). The main types of
cardiac arrest were as follows: 68% ventricular fibrillation/pulseless ventricular
tachycardia, 18% asystole and 14% electro-mechanical dissociation. Cardiac
arrest occurred mainly in the hospital (35% Emergency Department and 45% in
I/CCU). CPR was usually initiated in the hospital (Emergency Department 25%
and I/CCU 49%), and was successful in 68% of cases.
3.5 Acute Treatment Given
3.5.1 Aspirin/other anti-platelet administration
Aspirin or anti-platelet therapy can be given in the acute phase of suspected
ACS. The extent of this practice in the current sample is illustrated in table 3.23.
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Table 3.23: Administration of anti-platelet medications during the acute phase of
suspected ACS
Anti-platelet administration Suspected
AMI %
Suspected
Other ACS
%
Total %
Administered
Aspirin
Other anti-platelet
Aspirin or other anti-platelet
Both
84
30
85
24
64
31
65
19
77
31
79
22
Administration location*
Emergency Department
CCU
Other hospital area
Self-administered
GP-administered
Ambulance
69
9
3
2
9
4
68
9
4
3
9
4
69
9
3
2
9
4
Not administered**
Already taken anti-platelets
Unable to take orally
Contraindication
Unknown
15
42
14
13
25
35
63
0
5
14
21
52
7
9
19
*Patients may have been administered anti-platelets in more than one location
**There may be multiple reasons for the non-administration of anti-platelets
The majority of patients admitted were given an anti-platelet, and this mostly
occurred in the Emergency Department. Nine per cent of patients who received
anti-platelet medication received this medication from GPs, even though 53% of
patients were referred to the hospital by a GP (see table 3.1). Thus, 18% of
patients attending GPs received anti-platelet medication.
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3.5.2 Administration of thrombolysis
Thrombolysis is an appropriate treatment strategy for ST-elevation myocardial
infarction (STEMI). The national profile of the administration of this medication is
illustrated in table 3.24.
Table 3.24: Administration of thrombolytic therapy in 1994 and 2003
Details of thrombolytic therapy 1994 Census CCU 2003
Survey‡
Thrombolysed (%):
Suspected AMI on admission
Confirmed AMI on discharge
38
58
41
44
Location of thrombolysis administration (%):
I/CCU
Emergency Department
Other
96
2
2
48
48
4
Type of thrombolytic medication (%):
Streptokinase
Tenecteplase
Tissue plasminogen activator
Rapilysin
87
-
-
14
51
8
26
Reason for non-administration of thrombolysis (%):
Direct infarct angioplasty‡‡
No ST elevation‡‡
ECG unclear
Too late
History of haemorrhage
History of internal bleeding
Hypertension (HTN) (uncontrolled)
Suspected aortic dissection
Other
-
-
42
25
3
4
5
1
20
4
51
17
25
2
1
<1
<1
14
Thrombolysis figures do not include 4% of AMI patients who received direct infarct angioplasty
‡Of the patients admitted for suspected ACS, 2 were subsequently thrombolysed. Their data has
been omitted from the table above.
Data unavailable on other types of thrombolytic medication for 1994
‡‡These categories were added for the current survey
Although the overall rate of thrombolysis increased by 3% for suspected AMI
patients by 2003 (7% if including patients who received direct infarct
angioplasty), the rate had actually fallen by 14% (10% if including direct infarct
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angioplasty patients) in patients who were later confirmed as having an MI. This
may be as a result of changes in definitions of AMI, and is discussed later.
The location of administration of thrombolytic therapy has changed markedly
since 1994. Thrombolysis occurred in I/CCU in only half the percentage of cases
in 2003 compared to 1994 (48% v 96%), with a parallel increase in Emergency
Department thrombolysis from 2% to 48% of cases. This may explain the
decrease in hospital arrival to thrombolysis time from 76 minutes in 1994 to 45
minutes in 2003 (see table 3.13). In 2003, 22 hospitals (56%) thrombolysed
≥50% of patients in the Emergency Department. Fourteen hospitals (36%)
thrombolysed ≥80% of patients in the Emergency Department. Twelve hospitals
(31%) thrombolysed all of their patients in I/CCU.
The “no ST elevation” category as a reason for non-administration of
thrombolysis was added for the current 2003 survey. It was not envisaged as an
exclusive contra-indication to thrombolytic therapy, but on 41% of occasions it
was the only reason recorded. These scores may have been incorporated into
the “ECG unclear” category from 1994, and this may explain the disparity
between figures from the current survey and the previous study. Another factor
which changed from 1994 was uncontrolled hypertension as a reason not to
administer thrombolysis: there was a reduction from 5% to 1% over that period.
3.5.3 Direct infarct angioplasty
A more recent alternative to thrombolytic therapy is angioplasty to the site of
occlusion – direct infarct angioplasty. This treatment is currently available in a
limited number of centres. Available data on this process is displayed in table
3.25.
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Table 3.25: Time to treatment with direct infarct angioplasty for suspected AMI
patients
Details of direct infarct angioplasty Combined
Number (%) 39 (4%)
Treatment times:
Symptom onset to hospital
Hospital arrival to I/CCU
Hospital arrival to direct PTCA
Total – symptom onset to direct PTCA
2h 20mins
2h 44mins
3h 05mins
5h 05mins
3.6 Discharge
3.6.1 Discharge diagnoses
The discharge diagnoses of suspected ACS patients admitted to I/CCU are
outlined in table 3.26 (some patients may have more than one listed CHD
discharge diagnosis). These are the discharge diagnoses from I/CCU – the
hospital discharge diagnosis was not collected during this survey.
Table 3.26: Discharge diagnoses
CCU 2003 SurveyDischarge Diagnosis 1994 Census
(suspected
AMI)
%
 Suspected
AMI %
Suspected
Other ACS
%
Combined %
Complicated MI 28 30 4 22
Uncomplicated MI 42 61 15 46
Unstable angina 14 4 46 17
Other cardiac 9 7 19 11
Non cardiac 7 3 18 8
For suspected AMI patients, there was an increase in those patients diagnosed
as ‘Uncomplicated MI’ of 19% from 1994 to 2003, and a reduction in the
diagnosis of unstable angina (this may be due to changes in definition of AMI,
and is discussed later).
3.6.2 Discharge status
Of patients admitted to I/CCU with suspected ACS, 93% were discharged from
the hospital alive. Ninety per cent of patients admitted for suspected AMI were
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discharged alive, while 99% of patients admitted for suspected other ACS were
discharged alive. In 1994, the in-hospital mortality rate for confirmed AMI patients
was 11%. This has improved slightly to 9% for confirmed AMI patients in 2003.
Seventy per cent of patients were recorded as having been referred to cardiac
rehabilitation (i.e. phase I or later).
3.6.3 Cardiovascular medications on discharge
After the acute event, patients were discharged on many different types of
cardiac medications. Table 3.27 outlines the profile of cardiovascular medication
that patients were prescribed when discharged from I/CCU. Details of medication
on hospital discharge were not collected.
Table 3.27: I/CCU discharge medications (by inclusion criteria)
Cardiovascular Medication  Suspected
AMI %
Suspected
Other ACS %
Total %
Aspirin 81 81 81
Other anti-platelet 47 47 47
Beta-blocker 66 65 66
Alpha-blocker <1 1 <1
ACE inhibitor 56 50 54
Calcium antagonist 4 7 5
Statin 73 74 73
Nitrate 15 24 18
Diuretic 12 13 13
Anticoagulant 4 4 4
Glycoside 2 3 2
Potassium channel opener 2 4 3
Anti-arrythmic 3 4 3
Anti-anginal 1 3 1
Other* 1 2 1
* Angiotensin II antagonist, alpha agonist, unspecified anti-hypertensive
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The most common cardiac medications on I/CCU discharge were aspirin (81%),
statins (73%), beta-blockers (66%) and ACE inhibitors (54%). A high proportion
of patients were discharged on statins, even though the majority of patients were
not considered to have high levels of cholesterol (see table 3.7). This is in
accordance with current research on the prescription of statin therapy for CHD
patients with already low cholesterol levels.61 Eighty-five per cent of patients
were discharged on either aspirin or other anti-platelet medication.
Not all patients were discharged with a diagnosis of ACS (see table 3.26). For
patients discharged with confirmed ACS (AMI or unstable angina), the
medication profile on I/CCU discharge is shown in table 3.28 below.
Table 3.28: I/CCU discharge medications for diagnosed ACS (by inclusion
criteria)
CHD Medication  Suspected
AMI %
Suspected
Other ACS %
Total %
Aspirin 82 87 83
Other anti-platelet 47 55 49
Beta-blocker 67 75 69
Alpha-blocker <1 1 1
ACE inhibitor 56 51 55
Calcium antagonist 4 8 5
Statin 74 82 76
Nitrate 16 27 18
Diuretic 12 15 13
Anticoagulant 4 4 4
Glycoside 2 3 2
Potassium channel opener 2 4 3
Anti-arrythmic 3 5 3
Anti-anginal 1 3 1
Other* 1 3 1
* Angiotensin II antagonist, alpha agonist, unspecified anti-hypertensive
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When table 3.28 is compared to table 3.10 (which showed the medication profile
of admitted patients with a positive history of ACS), an increase in medications
for aspirin (8%), statins (23%), beta-blockers (20%) and ACE inhibitors (13%) is
seen.
A comparison with other recent European and international surveys is shown in
table 3.29.
Table 3.29: Comparison of cardiovascular medications at discharge in CCU 2003
with other recent surveys
CHD medication CCU 2003
(conducted
2003,
suspected
ACS
patients,
N=1356)
%
US (Burwen et
al 200362)
(conducted
1998-99, AMI
patients,
N=35713)
%
GRACE63
(conducted
1999-2000,
suspected
ACS
patients,
N=11543)
%
Euro Heart
Survey15
(conducted
2000-01,
ACS
patients,
N=10484)
%
EURO-
ASPIRE
II64
(conducted
1999-2000,
post-CABG
/PTCA
/AMI
patients)
N=3379)
%
Aspirin/anti-platelet 85 82.9 91 82.6-88.1 90
Statin 73 - 47 52.4-53.9 43
Beta-blocker 66 70.7 71 70.4-75.9 66
ACE inhibitor 54 70.8 55 52.3-62.4 38
Wide variation between the surveys on some medications is seen, but this may
partially be explained by the differences in recruitment between the surveys (e.g.
EUROASPIRE II interviewed patients at least 6 months post-discharge).
However, the current sample shows a high rate of prescribing statin therapy in
comparison to the other surveys, the difference ranges from a 19.1-30% greater
rate of prescribing.
3.7 Prevalence of depression in suspected ACS patients admitted to I/CCU
Depression is an independent risk factor for AMI morbidity and mortality. The
prevalence of depression was assessed by short-form questionnaires. Thirty-
eight of the thirty-nine hospitals undertook to give patients the depression scales
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during their I/CCU admission. The overall completion rate for the BDI-FS was
56%, with 66% completing the HADS. Not all patients were invited to complete
the scales. Taking this into consideration, the completion rates were 60% for the
BDI-FS, and 68% for the HADS.
A score of ≥4 in the BDI-FS was used to indicate the presence of depressive
symptoms in this study. A score of ≥11 was used for the depression scale of the
HADS-D, but scores of 8-10 may also be indicative of depressive symptoms (in
line with previous cardiac research.60 The findings for the depression scales are
displayed in table 3.30.
Table 3.30: Depression levels in suspected ACS patients as indicated by the
BDI-FS and HADS-D
Depression  Suspected
AMI %
Suspected
Other ACS %
Total %
BDI-FS
No depression (≤3)
Depression (≥4)
81
19
73
27
78
22
HADS depression scale
No depression (≤7)
Possible depression (8-10)
Depression (≥11)
85
12
3
78
16
6
83
13
4
The BDI-FS indicated a 22% depression rate in suspected ACS patients, while
the HADS depression scale rate was 4% depression for suspected ACS patients.
If the lower HADS depression scale cut-off point is used – in line with previous
research with the HADS on cardiac patients – the rate of depression for
suspected ACS patients increases to 17%. The 22% depression rate found by
the BDI-FS is marginally greater than the 17% rate found by the HADS (z=1.914;
p=.0556).
Table 3.30 indicates higher levels of depression in suspected other ACS patients
than suspected AMI patients (with both the BDI-FS and the HADS depression
scales). To test if this was significant, the scores for both scales were combined,
with patients scoring ≥4 on the BDI-FS and ≥8 on the HADS depression scale
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defined as ‘depressed’. A significantly higher rate of depression for the suspected
other ACS group was found (z=2.512, p<.05). Possible reasons for this are
discussed later.
Previous research has suggested that more women experience depression after
AMI, and that depressed patients may spend more time in the hospital.65 In the
present study, no effect of gender was seen for depression scores (z=-0.590;
p>.05), and depressed patients did not spend longer in hospital (z=0.484; p>.05).
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Chapter 4
Discussion
4.1 General discussion
The findings of the present research provide a comprehensive overview of the
current presentation and management of suspected ACS patients in Ireland. This
study built on the previous research conducted in 1994, but also expanded its
findings beyond suspected AMI patients to all ACS patients. It also, for the first
time in Ireland, provided a measurement of the extent of depression in post-ACS
patients, and evaluated the feasibility and value of using short-form psychological
questionnaires in an acute setting.
4.2 Discussion of results
4.2.1 Demographic and risk factors
In terms of demographic details, the first finding of note in this survey was the
comparability across the samples of hospital admissions from 1994 to 2003. Full
data on the 1994 sample is not available, but the areas that were compared were
very similar. This shows that the population cohort presenting with AMI (and
other ACS) has remained unchanged over time.
Presentation with suspected AMI was the first incidence of acute CHD for the
majority of patients admitted for suspected AMI (64% with no CHD history),
whereas patients admitted for suspected other ACS tended to have had more
past events (40% with no CHD history). The rate of self-referral for suspected
AMI patients had increased by 15% since 1994. The reasons for this increase
are not clear from the present survey. This trend deserves further investigation.
Most patients were part of the GMS scheme (70% of the total sample), with 38%
of patients under 70 years of age covered by this scheme. The majority of
patients were smokers or ex-smokers (72%).
Forty per cent of the sample had a past history of hypertension, with 17% of
these patients not on any current form of treatment for their hypertension. This
proportion may include patients who had hypertension that subsequently
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improved with treatment or lifestyle changes, and the treatment was no longer
deemed necessary. In terms of hypertension being cited as a contraindication to
thrombolysis, a reduction in untreated hypertension was seen in 2003 compared
with 1994. It is not clear from the data whether this reduction (5% in 1994 to 1%
in 2003) is from changes in practice at the acute phase (i.e. uncontrolled
hypertension considered less of a contraindication to thrombolysis, or
uncontrolled hypertension being controlled more efficiently during the acute
phase), or if more patients are now being prescribed medication to control
hypertension in primary care prior to an acute event.
Not all patients admitted for suspected ACS had their cholesterol levels
measured. Hospitals tested 88% and 83% for total cholesterol and triglycerides
respectively, while 53% of patients had HDL and 51% had LDL cholesterol
recorded. There is scope for improvement in this area.  The majority of patients
in the current sample were within currently accepted parameters for cholesterol
levels, yet these patients were admitted to I/CCU with an acute ACS event. The
prevalence was lowest for HDL cholesterol, with 15% of the sample within
‘desirable’ limits for HDL and a further 48% within ‘acceptable’ limits. Most
patients (73%) were discharged on statin therapy. This is in line with current
research on statin therapy which recommends prescribing statins even to
patients with already low cholesterol levels.61 Patients with a past history of ACS
had significantly lower total and LDL cholesterol levels. This may be accounted
for by the fact that these patients would probably have already been prescribed
lipid-lowering medications. Patients who had been taking statins prior to the
current admission had significantly lower total and LDL cholesterol levels.
A 43% positive family history for CHD was seen in this sample. This level is
above the rates reported in the Euro Heart Survey15, i.e. 23.1-29.3% positive
family history for CHD. This may be due to the missing data in this case – no
answer was given for 9% of the total sample for this question. Data collectors
may have left the field blank instead of indicating that there was no family history
if CHD.
A 15% rate of pre-admission diabetes was reported. The rates found in the
present survey are similar to the 14-22% rates of diabetes in ACS patients in a
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recent Irish survey66, and is comparable to international research on non-ST-
elevation ACS67 and CHD.68 This high rate of diabetes is consistent with a cohort
of older patients and also reflects the role of diabetes as a risk factor for CHD.
The majority of patients in the sample (62%) were already taking cardiovascular
medications prior to this admission. This was due to the rates of prior CHD (43%)
and rates of hypertension (40%) already existing in the sample. Of these
medications, aspirin (39% of the total sample), statins (27%), beta-blockers
(26%) and ACE inhibitors (24%) were the most commonly prescribed. Patients
with a past history of ACS were taking mainly aspirin (75%), statins (53%), beta-
blockers (49%) and ACE inhibitors (42%).
An increase in pre-admission cardiac revascularisation  (CABG and PTCA)
history, from 6% in 1994 to 16% (10% of suspected AMI and 27% of suspected
other ACS) in 2003 was seen. This probably reflects the increased availability of
interventions since 1994.
4.2.2 Treatment times
In terms of total time to treatment (symptom onset to thrombolysis or direct
PTCA, or symptom onset to I/CCU admission if the patient did not receive one of
these treatments) an increase in time has been seen over the course of the last
nine years, with suspected AMI patients now waiting 6h 05mins to be treated, an
extra 1h 35mins than was the case in 1994. However, this figure disguises the
significant progress that has been made in the treatment of AMI patients who
receive thrombolysis, which has yielded faster ‘door-to-needle’ times. Suspected
AMI patients who received thrombolysis in the 2003 sample were being treated
more quickly than in 1994 (median 45mins v 76mins).
The transfer of thrombolytic administration from the I/CCU (96% in 1994) to the
Emergency Department (48% in 2003, with 48% administered in I/CCU) is
probably the main reason for the decreased time to treatment for thrombolysed
patients. The present survey found that 36% of hospitals thrombolysed ≥80% of
patients in the Emergency Department, and 56% of hospitals thrombolysed
≥50% of patients in the Emergency Department. It is not clear, however, that an
additional shift of thrombolysis to the Emergency Department in the remaining
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hospitals would also result in a further reduction of ‘door-to-needle’ time. This is
because some hospitals already adopt a ‘fast-track’ policy, where chest pain
patients are admitted directly to CCU, bypassing Emergency Department
assessment. Adopting a strategy of Emergency Department thrombolysis may
have little or no effect in these cases.
Although progress has been made since 1994 in terms of ‘door-to-needle’ times
for thrombolysed patients, there is still scope for improvement for hospital delay
times. Recommendation 8.4 of the Cardiovascular Health Strategy outlines a
‘door-to-needle’ time of 30 minutes. The present survey found that 35% of
patients were being thrombolysed within this time frame.
Suspected AMI patients who did not receive thrombolysis waited significantly
longer for a treatment endpoint (i.e. transfer to I/CCU) than those who received
thrombolysis. This cohort is responsible for the increase in total time to treatment
seen since 1994. The reasons for this are not fully clear at present, and further
investigation is necessary. The data showed that patients (who were
subsequently confirmed as having an AMI) who were not thrombolysed
presented to hospital significantly more slowly than did patients who received
thrombolysis. These patients presented to hospital with a similar time-lapse from
symptom onset as did patients who presented with suspected other ACS. This
may indicate the less severe symptoms of unstable angina and non-ST-elevation
myocardial infarction (NSTEMI).
Suspected AMI patients who did not receive thrombolysis also took significantly
longer from hospital arrival to arrive in I/CCU than did patients who received
thrombolysis. It may be that triage, and the development of chest pain
assessment units (CPAUs) and other similar units (e.g. medical admission units
(MAUs)), which involve the initial screening of chest pain patients to determine
whether the pain is cardiac in origin prior to transfer to I/CCU, have skewed the
data in the current survey. A typical scenario may be that a patient currently
arrives at hospital, without ST elevation when assessed by ECG, and is
assessed for some time in the CPAU to either ‘rule-in’ or ‘rule-out’ ACS. In the
past, this type of patient may have been admitted directly to I/CCU. Patients may
also be triaged into groups reflecting the necessity for immediate treatment, and
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NSTEMI and unstable angina patients may be detained for observation in the
Emergency Department. It may also be that pressure for I/CCU bed places is
more quickly resolved for the more acute STEMI patients. However, further
prospective observational research on this aspect of care is required.
In 1994, patients presenting who were later confirmed as having had an AMI
presented to hospital earlier than did the rest of the sample. This finding was not
replicated in the current survey. This may be because of a change in definition of
AMI which is discussed later, which means that patients with possibly less severe
symptoms are now included in the confirmed AMI cohort. It is possible that these
patients would not present to hospital as quickly as patients with more severe
symptoms, thus increasing median delay time for this group.
Suspected other ACS patients presented to hospital in time frames similar to
suspected AMI patients who did not receive thrombolysis, but were not admitted
to I/CCU as quickly. This may reflect the triaging of patients in the Emergency
Department, where patients labelled as suspected AMI were treated more quickly
than those labelled as suspected other ACS.
Patient delay prior to hospital arrival is still the biggest impediment to improving
treatment times for AMI and other ACS. Patients who were referred via a GP had
a significantly longer time to treatment than those who self-referred in both 2003
and 1994. It seems that distance from hospital is a factor in this, as patients who
self-referred tended to be closer to hospital at the time of symptom onset.
Clearly, in the present system, although substantial improvements have been
made since the mid-1990s, recommendation 7.16 of the Cardiovascular Strategy
outlining a ‘call-to-treatment’ time of 90 minutes is not currently being met. The
present survey found that 29% of patients were thrombolysed within 90 minutes
of calling for professional help.
Future research and resources need to concentrate on a reduction in time to
treatment for pre-hospital factors. Strategies to best address this issue need to
be addressed by the professional groups concerned. A number of psychological
studies have provided detailed examination of patient contributions to delayed
help-seeking for AMI.69-72 These highlight possibilities for intervention to reduce
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symptom onset to help-seeking times but caution against a simplistic public
education campaign approach. Since general public advertising/education
campaigns have little efficacy69 70 73, and even a previous experience of AMI has
no effect on pre-hospital call for assistance times, this problem needs to be
addressed with a sophisticated approach. One approach is to authorise health
professionals in the pre-hospital setting to administer thrombolysis. Ambulance
personnel and GPs are the two most obvious choices. The administration of
thrombolysis by EMTs has been shown to reduce time to treatment in other
studies.24 A recently completed GP thrombolysis study showed the practicalities
of this approach in an Irish setting.34 In the hospital setting, nurse-led
thrombolysis has been shown to be an effective way of reducing treatment
times.25 26 The provision of more mobile coronary care units (MCCUs) may also
be an answer to reducing delay times in rural areas.74
4.2.3 Acute treatments received
Not considering the 4% of suspected AMI patients who received direct infarct
angioplasty, a slight increase was seen in the use of thrombolysis for suspected
AMI patients (38% in 1994 and 41% in 2003), although this figure has fallen for
confirmed AMI patients (58% in 1994 to 44% in 2003). This reduction in
thrombolysis for confirmed AMI patients may be due to changes in the definition
of AMI in 2000.16 This change increased the proportion of patients diagnosed as
having an AMI by including patients who would previously be diagnosed as
unstable angina. This has had a marked effect on discharge diagnoses in the
UK17 and in the US18, and may be the reason for the apparent fall in rates of
thrombolysis here (the discharge diagnosis of unstable angina in suspected AMI
patients fell from 14% in 1994 to 4% in 2003, with a corresponding increase of
21% in AMI discharge diagnoses). This change, coupled with improved
admission diagnosis techniques, may explain this increase (there has also been
a reduction in ‘non-cardiac’ discharge diagnoses for suspected AMI patients from
7% in 1994 to 3% in 2003). This change has implications for clinical and
epidemiological practice, and even insurance providers.18 19 It also has further
knock-on implications for subsequent mortality rates, with the rates of mortality
for AMI decreasing due to the inclusion of less serious conditions into this
cohort.18
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A marked decrease in the use of streptokinase (SK) as first choice thrombolytic
agent has occurred over time. In 1994 SK was used in 87% of cases, but it was
used in 14% of cases in the present study. The most popular thrombolytic drug in
the current survey was tenecteplase (metalyse), used with 51% of thrombolysed
patients.
Direct infarct angioplasty was provided as an alternative therapy for 41 patients
(39 suspected AMI, or 4%). Hospital arrival to direct PTCA was over 3 hours.
However, this treatment has been shown to be superior to thrombolysis even
when administration is delayed longer than thrombolytic therapy.75-79 Due to the
small number of patients in the current sample who underwent direct PTCA, it is
difficult to directly compare this treatment to thrombolysis. However, the ‘door to
balloon’ time of 60 minutes recommended by the European Society of
Cardiology4 was not being met in the majority of cases (see section 3.5.3).
The administration of anti-platelet medication during the initial presentation was
79%. This is below the levels reported in other surveys in Europe (Hasdai et al15
report an 83-93% rate of anti-platelet administration on admission across
European countries), the United States (Burwen et al62 report an 82.9% rate of
aspirin administration) and internationally (the GRACE63 study reports a 91% rate
of aspirin administration). More anti-platelet administration could occur at an
earlier phase. Given that over half (53%) of the sample were referred by a GP,
and that 44% arrived in an ambulance, it should be possible to increase aspirin
administration from GPs or in ambulances to more than the 13% at which it
currently stands. ‘Refresher’ courses in treatment for suspected ACS may be
beneficial. Indeed, this has already occurred in the DARTS34 programme, where
GPs who attended an acute cardiac care programme gave aspirin significantly
more often to AMI patients (55% of patients) than control GPs (16% of patients).
4.2.4 Discharge status
In the current survey, discharge details from I/CCU were analysed. No data
(except in-hospital mortality and hospital discharge date) were collected post
I/CCU discharge.
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As outlined previously (section 4.2.3), a significant change in discharge
proportion of ‘uncomplicated MI’ has occurred, with an 18% increase for
suspected AMI patients from 1994 to 2003. This has led to a corresponding
reduction in unstable angina diagnoses (10% reduction). There has also been a
slight reduction in ‘non cardiac’ discharges for suspected AMI patients (7% in
1994 to 3% in 2003), which may indicate an improved accuracy in initial
diagnosis of patients.
A slight decrease in in-hospital mortality rates was seen (11% in 1994 and 9% in
2003) for confirmed AMI patients. Again, this may be partially attributed to
change in definition.18 Only 1% of patients admitted for suspected other ACS
died in hospital. It was beyond the remit of the present survey to investigate
deaths prior to hospital admission. A more complete reflection of mortality from
ACS requires a population registry. Community mortality from AMI levels may be
as high as 69.2%.80
For patients who were admitted with a past history of ACS, an increase was seen
in the proportion of prescribed cardiovascular medications from admission to
I/CCU discharge. Confirmed ACS patients were prescribed more aspirin (an
increase of 8%), statins (23% increase), beta-blockers (20% increase) and ACE
inhibitors (13% increase). These increases reflect greater adherence to clinical
guidelines4 81 on discharge medications for ACS, and although an improvement,
these rates still did not achieve the recommended rates of prescription (aspirin
excepted). The most common cardiac medications on I/CCU discharge (for the
total sample) were aspirin (81%), statins (73%), beta-blockers (66%) and ACE
inhibitors (54%). Eighty-five pre cent of patients were discharged on either aspirin
or other anti-platelet medication. With the exception of aspirin, these figures fall
short of the targets set by the NSF in the UK (2000)7, which call for 80% of
patients discharged with AMI to be prescribed aspirin, beta-blockers and statins
by the year 2002. No data were collected on contra-indications to medications,
so it is not possible to speculate why these rates for CHD medications are not
higher. Medication prescription may also have changed from I/CCU discharge to
hospital discharge.
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A high proportion of patients were discharged on statins, even though the
majority of patients were not considered to have high levels of cholesterol (see
table 3.7) in terms of population norms. In comparison to other recent
international surveys, the rate of statin therapy on discharge is much higher in
the current survey, with up to 30% more patients being discharged on statins
after a suspected cardiac event in Ireland than in other countries (however, the
international studies used for comparison were completed from 1998-2001 and
clinical practice is evolving so rapidly in these areas of statin prescribing that
rates in these other countries are likely to have changed by 2003). This
prescribing level is in accordance with more recent findings on statin therapy,
which recommend the prescription of statins for CHD patients with already low
cholesterol levels.61
Not all patients were provided with Phase I cardiac rehabilitation. The present
survey found that 70% of patients received this in-hospital service. However, it
may be that hospital staff frequently provide advice post-ACS event in line with
Phase I cardiac rehabilitation guidelines, but that this advice is not labelled as
such in these centres. These centres should at minimum use the accepted
terminology for these practices. In line with recommendation 9.6 of the
Cardiovascular Health Strategy, all patients should receive Phase I cardiac
rehabilitation.
4.2.5 Depression in ACS patients
The findings of this study show a substantial level of depression in post-ACS
patients. These levels are in line with previous research on depression in cardiac
patients36 37 45 46 82, which find levels of depression between 15-20% after an
acute event.
There was some disparity in performance between the questionnaires, with
higher response rates for the HADS (60% for the BDI-FS and 68% for the
HADS), while the BDI-FS found a marginally higher prevalence of depression
(22% for the BDI-FS, and 17% for the HADS depression scale when a cut-off of
≥8 is used). The findings showed a significantly greater level of depression in the
suspected other ACS sample than the suspected AMI sample. One reason for
this could be the higher proportion of suspected other ACS patients who already
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had a coronary history (60% had previous CHD and 31% had a previous AMI,
while 36% of the suspected AMI sample had prior CHD, and 16% had
experienced an AMI previously). Previous research has also reported a higher
rate of depression in post-AMI patients with a history of angina 83 and in unstable
angina patients with a prior history of CHD events.84
Previous studies of depression in this area have typically involved a trained
mental health professional to assess patients after AMI.36 42 85 This approach has
research advantages but is not feasible in most clinical settings. The present
survey has shown that short self-report screening instruments, the BDI-FS and
the HADS depression scales, are an acceptable substitute for identifying patients
who are most at risk for CHD-related depression. These results also show that
the use of short-form psychological assessment scales can be of benefit in the
acute setting. They may be useful in drawing attention to possible mood
disturbance in an environment where this would not be routinely assessed.
These instruments are screening tools only, but can identify those patients
requiring further observation or assessment in the cardiac setting.
The treatment of depression in ACS patients has not been shown to reduce
subsequent mortality, but it does improve quality of life.86 Also, since depressed
AMI patients place a greater demand on healthcare resources87, identification
and treatment of this group of patients is advisable, both for providers and
patients.
Recently, the United States Preventive Services Task Force88 has recommended
that primary care professionals use these types of screening tools to assess
patients for depressive symptomatology in clinical practice. We have shown that
the HADS and BDI-FS are useful in an acute setting, and use of brief
assessments such as these may become more common in the future.
4.3 Survey limitations
This survey was intended to provide a national profile of the presentation and
management of ACS in Ireland. A national survey such as this cannot account for
all cases of ACS. Patient death from ACS prior to hospital arrival has already
been discussed. It should also be noted that not all hospitals admit every
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suspected ACS to I/CCU – certain hospitals will admit both suspected AMI and
suspected other ACS to other wards, depending on the severity of the event and
the availability of I/CCU beds. The data in this survey do not account for these
management differences. Therefore the throughput of ACS in any given hospital
is not accounted for by this survey. Instead, the throughput of suspected ACS
patients admitted to I/CCU is documented.
Although all physicians and data collectors were provided with definitions of ACS
and AMI, this survey did not seek to assess local definitions. This may have lead
to some disparity between what was classed as ‘suspected AMI’ and what was
classed as ‘suspected other ACS’ between physicians and between hospitals.
This was also the case in the previous 1994 census.8 In effect, the survey
assesses the working definitions of AMI and other ACS in each of the
participating hospitals and these ‘working definitions’ need to conform to the
goals for most effective management of ACS. The inclusion of the suspected
ACS cohort in this survey provided a safeguard that data on all suspected ACS
(STEMI, NSTEMI, unstable angina) patients admitted to I/CCU were included.
Any disparity across physicians or across hospitals was likely to be nullified, as
patient data were still collected, whether or not they were labelled as ‘suspected
AMI’ or ‘suspected other ACS’.
The present study has highlighted the need for a national prospective registry of
ACS. The value of such registries has been shown in other countries. For
example, registries increase the use of reperfusion therapy where necessary, but
to ensure this practice continues they need to be ongoing.89 In the UK, the
introduction of the Myocardial Infarction National Audit Project (MINAP)90 has
contributed to an increase in the numbers of patients thrombolysed within
recommended timescales. After the publication of the NSF guidelines on CHD in
20007, 79% of patients were being thrombolysed within 30 minutes of hospital
arrival in 2002; this compares with 38% of patients meeting a ‘door-to-needle’
time of 30 minutes before 2000.91 Registries can also underscore the extent of
adherence to international guidelines. The current data highlight progress in
some areas but indicate that improvements need to occur in other aspects. A
national registry can illustrate the areas which need further investment, and those
areas which can be improved by changes in procedures. The monitoring of
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guideline adherence should even be considered a part of optimal practice
procedures.92
4.4 Conclusion
Significant progress in some aspects (e.g. time-to-thrombolysis) of care for
suspected ACS has occurred, but there is still scope for improvement in these
areas. A necessary goal is to increase the proportions of patients seen within the
recommended time. Other aspects of ACS care also now require attention (e.g.
hospital delay for patients who do not receive/require thrombolysis). The
implementation of a national registry would allow resources to be focused on
these aspects and facilitate routine health care monitoring. Also, for the first time
in Ireland, steps have been taken to identify a brief method to identify patients
who may have a poorer prognosis post-ACS due to mental health issues or who
require attention for mental health issues post-event. Further investigation into
these areas needs to be conducted.
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Chapter 5
Recommendations
5.1 Recommendations
Recommendations from this study are made in the context of the development of
an ongoing system of registration of ACS – the Coronary Heart Attack Ireland
Register (CHAIR). Thus the focus is on specific recommendations particular to
the findings in this survey. More general issues such as the need for unique
patient identifiers to track patients throughout the healthcare system are not
addressed.
Pre-hospital phase
1. Strategies to reduce pre-hospital time to treatment need to be
developed or expanded. These may include GP thrombolysis, emergency
medical technician (EMT) thrombolysis or mobile coronary care units
(MCCUs). As previously outlined, these options are feasible in the current
context.
2. Strategies should be developed to increase the pre-hospital
administration of aspirin. In the pre-hospital phase 9% of patients received
aspirin from GPs, 4% in the ambulance and 2% of patients self-administered
aspirin. There is capacity for improvement in this aspect of the pre-hospital
phase. GPs and EMTs should be offered training in the immediate care of
patients with suspected ACS.
3. Strategies to reduce time from onset of symptoms to patients’ call for
help should be considered on the basis of available evidence. Of
particular note are strategies which would encourage prompt and appropriate
action by those with a previous cardiac event. Simplistic public education
campaigns have been shown to have little ongoing efficacy. By using
available evidence a sophisticated strategy focusing on relevant
psychological aspects of delay could be implemented.
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Hospital phase
4. A policy of Emergency Department thrombolysis for all eligible patients
should be considered. It is clear from the present survey that the increased
implementation of Emergency Department thrombolysis since 1994 was a
factor in the reduction of hospital delay times. Although this may not be
feasible in all cases, a further shift towards Emergency Department
thrombolysis by the remaining centres may increase the numbers of patients
treated within the recommended times. In appropriate centres all patients
should be assessed in the Emergency Department as to whether they should
receive thrombolysis or proceed to direct infarct angioplasty.
5. Support should be provided to increase availability of direct infarct
angioplasty facilities. Four per cent of suspected AMI patients in the
current survey received this treatment. An increase in the availability of this
treatment, which is superior to delayed thrombolysis, would be beneficial.
Implementation of guidelines for care of patients with suspected ACS should
consider strategies to increase access to primary percutaneous coronary
intervention.
6. Recommended times to treatment (90 minutes from call to professional
help, 30 minutes from hospital arrival) should be adopted  by each
centre providing care to patients with suspected ACS. Centres should
monitor the proportion of patients achieving these targets on an
ongoing basis. Continuous audit of performance can lead to an increase in
adherence to clinical guidelines. Without audit, it is unlikely that these targets
will be met.
7. The measurement of cholesterol for suspected ACS patients should be
adopted as standard. Although 88% of patients had their cholesterol levels
tested, it should be feasible to test all suspected ACS patients.
8. Further research should evaluate the screening of patients for
depression in the acute phase of an ACS event. The present study has
shown the feasibility of using short-form questionnaires in an acute clinical
setting. Further research on this area needs to be conducted to ascertain the
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clinical effectiveness of these measures, and how the findings can be best
used in clinical practice.
Post-hospital phase
9. Prescription of cardiovascular medications post-ACS should adhere to
current professional guidelines. Although the guideline levels for aspirin
prescription (81%) were reached, prescription of beta-blocker (66%) and
statin (73%) therapy levels were below recommended levels.
10. Referral for cardiac rehabilitation services should be undertaken for all
patients in line with professional guidelines. In line with recommendation
9.6 of the Cardiovascular Strategy, all patients should be provided with
Phase I cardiac rehabilitation. The present survey found a referral rate for
Phase I cardiac rehabilitation of 70%.
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Appendix A - Definitions
Inclusion Criteria & Definitions for CCU 2003 National Survey
Information for Clinicians and Data Collectors
Inclusion Criteria: Suspected Acute Coronary Syndrome (ACS) patients admitted to
I/CCU. This includes patients with an admission diagnosis of either acute myocardial
infarction or unstable angina.
Sample: Collection of data starts 20th Jan 2003. Collection of data ceases when 25
suspected acute myocardial infarction (AMI) patients are sampled (initial admission
diagnosis = suspected AMI). The data is also collected on all other (I/CCU) admitted
ACS patients, from start date of 20th Jan 2003 until the data collection is completed for
the 25th suspected AMI patient.
The above criteria will result in five (general) diagnosed groups of patients:-
1. AMI
2. Unstable Angina
3. Other ACS (e.g. after percutaneous coronary intervention). See comment after (d)
in definition below
4. Other cardiac
5. Non-cardiac
Further information on definitions of ACS:
Definition of ACS (Consensus statement of the Joint European Society of
Cardiology/American College of Cardiology Committee, 2000): ACS includes cardiac
events previously referred to as unstable angina, non-ST-segment-elevation myocardial
infarction (MI), and ST-segment-elevation MI.
ACS is now used to describe a spectrum of clinical presentations that share an underlying
pathophysiology, replacing the previous nomenclature of ischaemic chest pain. The
definition of acute coronary syndrome includes patients presenting with ischaemic
cardiac chest pain in the following categories:
(e) Unstable angina,
(f) non Q wave myocardial infarction
(g) Acute Myocardial infarction with ST segment elevation and Q wave development
(h) An additional category includes patients who experience abrupt closure of a
coronary artery during percutaneous coronary interventions.
Definition of Acute Myocardial Infarction (AMI): Criteria for acute, evolving or recent
MI: either one of the following:
(1) Typical rise and gradual fall  (troponin) or more rapid rise and fall (CK-MB) of
biochemical markers of myocardial necrosis with at least one of the following:
(e) ischaemic symptoms,
(f) development of pathologic Q waves on the ECG;
(g) ECG changes indicative of ischaemia (ST segment elevation or depression) or
(h) coronary artery intervention (e.g. coronary angioplasty)
(2) Pathologic findings of an acute MI
The Joint European Society of Cardiology/American College of Cardiology Committee,
(2000). Myocardial infarction redefined – a consensus document of for the redefinition of
myocardial infarction.  Eur Heart J,  21(18), 1502-1513.
PMID: 10973764
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GRACE Definitions - ACS: UA & AMI
Use this section if more detail is needed on definitions above.
Fox KA, Goodman SG, Klein W, Brieger D, Steg PG, Dabbous O, Avezum A.
Management of acute coronary syndromes. Variations in practice and outcome; findings
from the Global Registry of Acute Coronary Events (GRACE).
Eur Heart J. 2002 Aug;23(15):1177-89.
PMID: 12127920 [PubMed - indexed for MEDLINE]
ACS (including unstable or intermediate coronary syndromes AND/OR AMI)
Unstable or intermediate coronary syndromes:
Symptoms felt to be consistent with acute cardiac ischaemia within 24h of hospital
presentation with serial enzymes negative for myocardial infarction.
And at least one of the following:
 ECG Changes:
o Transient ST segment elevation of ≥ 1mm
o ST segment depression of ≥ 1mm
o New T wave inversion of ≥ 1mm
o Pseudo-normalisation of previously inverted T waves
 Documentation of coronary artery disease:
o History of MI, angina, congestive heart failure felt to be due to ischaemia
or resuscitated sudden cardiac death
o History of, or new, positive stress test with imaging
o Prior, or new, cardiac catheterisation documenting coronary artery disease
o  Prior, or new, percutaneous coronary intervention or coronary artery
bypass surgery
Note: Patients with unstable or intermediate coronary syndromes who are hospitalised for
<1 day cannot qualify for GRACE based on symptoms and history alone (i.e., they must
have one of the ECG changes or new documentation of coronary artery disease as listed
above)
Acute Myocardial Infarction:
Symptoms felt to be consistent with cardiac ischaemia within 24h of hospital presentation
And at least one of the following:
 Increase in cardiac enzymes
o CK-MB > 2 x upper limit of the hospital’s normal range OR if no CK-MB
available. Then total CPK >2 x upper limit of the hospital’s normal range
o Positive troponin I
o Positive troponin T
 ECG Changes
o New Q-waves (one-third the height of the R wave or > 0.04 s)
o New R wave > S wave in lead V1 (posterior myocardial infarction)
o New left bundle branch block
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Appendix B - Audit Form
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CCU 2003 QUESTIONNAIRE
HOSPITAL 00
Inclusion Criteria: (Suspected)  ACS  AMI
A. Personal Details
1.Hospital Chart Number: _  _  _  _  _  _  _  _  _
2 Name _____________________________
3. Address _____________________________
_____________________________
4. Urban Rural Unknown
5. Date of Birth _ _ / _ _ / _ _ _ _
6. Sex:   M F Unknown
7. Employment
Fulltime Part time  Unemployed
House duties Disability benefit  Retired
Student Unknown
8. Occupation (of principal earner)__________________
9. Insurance type:  None Medical Card Employer
VHI/BUPA  Unknown  Other _____________
10. Family GP: Name ___________________
Address ________________________________
____________________________________________
B. Risk Factors
1. Smoker: Current/ex smoker (<6 months)
 ex-smoker (>6 months)   Never unknown
2. Hx of hypertension Yes No
If yes: On drug treatment Diet Exercise
3. Lipid profile when in unit (If Available)
Total Cholesterol   ______m/mol/l Unavailable
HDL ________m/mol/l Unavailable
Triglycerides ________m/mol/l Unavailable
LDL ________m/mol/l Unavailable
4. Previously taking: Betablockers Statins  ACE
inhibitors Anti-platelet Aspirin
Other CHD Drugs ________________________
5. Previous CHD History: None MI
Angina Pectoris Recent onset angina (<1 month)
Other ______________________  Unknown
6. Immediate Family CHD History (Male at age <
55 years; Female at age <65 years)     Yes No
7. Hx of diabetes: No IDDM (type I) 
Non-IDDM (type II) Unknown
8. Coronary Interventions: None  PTCA CABG
PTCA+Stent Other ____________________
C. Dates and Times TIME 24HR DATE: DD-MM-YY
1. Symptom onset _ _ : _ _ _ _ / _ _ / 03
2. Call for professional help _ _ : _ _ _ _ / _ _ / 03
3. Arrival at Hospital _ _ : _ _ _ _ / _ _ / 03
4. Admission to I/CCU _ _ : _ _ _ _ / _ _ / 03
5. Thrombolysis given _ _ : _ _ _ _ / _ _ / 03
6. Direct infarct angioplasty _ _ : _ _ _ _ / _ _ / 03
7. I/CCU discharge _ _ : _ _ _ _ / _ _ / 03
8. Hospital discharge _ _ : _ _ _ _ / _ _ / 03
D. Admission details
1. Referral source:  Self GP Other ________
2. Admission Mode:
Cardiac Ambulance Other ambulance Car (Self)
Car (Passenger) Other _______________________
3. Was mobile CCU involved: Yes No
4. I/CCU admission route:
Via A&E Via ambulance/mobile CCU
Other hospital transfer In patient transfer
Other_________________
5. Approx distance from hospital at onset of
symptoms:   miles
6. Activity engaged in at onset of symptoms
__________________________________
7. Cardiac arrest: Yes* No (go to q E1)
*7a Hospital/A&E Unit Ambulance Other____
*7b Asystole VF/Pulseless VT EMD
Unknown Other _____________
8. CPR initiated by:
Member of public Healthcare Professional
I/CCU Ambulance  A&E Not applicable
9. Outcome successful: Yes  No Unknown
E. Acute Treatment Given
1. Aspirin given for acute episode: Yes* No**
Anti-platelet given for acute episode: Yes* No**
* By: Self GP Ambulance A&E
** Reason aspirin/antiplatelet not given? Unknown
Previously taking aspirin Contraindication
Refused    Unable to take drug orally Other_______
2. Thrombolysis given:
Yes* No (Go to question E3)
*2a. Administration  
I/CCU Hospital/A&E Cardiac Ambulance
Other ambulance GP
Other ___________________
*2b. Type given: SK tPA TNK
UK Other _____________
3. If thrombolysis not given tick reason(s)
Direct infarct
angioplasty
 R e c e n t  P C I
(PTCA/Stent)
 H x  o f
haemorrhage
ECG unclear Recent surgery Liver disease
Prolonged CPR Recent CVA Pregnancy
 N o  S T
elevation
 Suspected aortic
dissection
Recent
trauma
Drug
contraindication
Hx internal bleeding Uncontrolled
hypertension
Too late Unknown Other________________
F. Discharge
1. Discharge diagnosis
Complicated MI Uncomplicated MI Unstable angina
Other cardiac
ischaemia
Other Cardiac Non cardiac
Other ___________________
2. Discharged on: Betablockers Statins
ACE inhibitors Anti-Platelet Aspirin
Other CHD drugs ______________________
3. Discharge status: Alive
Died I/CCU Died other _______________
4. Referred to cardiac rehab: Yes No Unknown
Any comments/unusual circumstances: ________
________________________________________
________________________________________
________________________________________
Staff Signature: ________________
Date:          /       /03
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Appendix C – Consultant Information Letter and
Consent Form
Dear Dr ________,
We are writing to inform you about CCU 2003, a national survey supported by a
research grant from the Department of Health and Children through the Cardiovascular
Strategy.  The survey will document aspects of care of patients who are admitted to
coronary care units/intensive care units with chest pain.  This study will repeat and
update information gathered in previous similar surveys in Ireland in the 1990s, taking
into account changes in treatment and classification of cardiac diseases. It will also for
the first time in Ireland assess the mental health of ACS patients post the acute phase of
their treatment. The purpose of the study is to document current care, compare it with
previous surveys, provide a baseline for future studies, and to provide information
allowing each centre to focus on making appropriate changes to improve their systems if
necessary.
Each hospital or centre admitting patients with chest pain to an ICU or CCU was
approached to take part in the study. The survey has been approved by the relevant Ethics
Committee in your hospital/area. Please find enclosed documents pertaining to this
survey, including protocol, CCU 2003 questionnaire, case definitions for guidance, and
depression questionnaires. The survey will commence on 20th January 2003.
Obviously, consent from all consultants who admit patients to I/CCU is required for
patients to participate in this survey. We would appreciate if you could review the
attached information and provide us with your consent to include your patients in the
above survey. Also enclosed is a consultant consent form for the survey, which you can
either return to your hospital contact XXXXXXX or send directly to us.
If you require any further information on this matter, XXXXXXX will have further
details in your hospital.  Alternatively, you can contact the Research Officer
(XXXXXXX) or any of the undersigned with any queries.
Yours sincerely,
_______________
CCU 2003 Survey
Hospital Name: XXXXXXX
Consultant Name: XXXXXXX
I, the undersigned agree that the study investigators may record clinical details of patients
with chest pain admitted under my care to CCU/ICU in line with the study protocol.
…………………………………………………………………………………………..
Signature                                                                                                 Date
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Appendix D – Patient Information Form
Patient Information Leaflet for CCU 2003 Survey and Follow-up Study
CCU 2003
This hospital is taking part in a national survey of the care of patients admitted to hospital with chest pain.
The survey will give us information on the care of patients in 2003 and will show if the care of patients has
changed since previous surveys in the early 1990s. This will help to identify if there are areas where
further improvements are needed. You will be asked if you are willing to take part in this study
Follow-up study
As part of a follow-up study, a number of the patients from the CCU 2003 study may be contacted in about
a year’s time to see how they are doing. You will be asked if you are willing to be included in the list of
patients who may be contacted next year.
What does the research involve?
In order to collect the required information we need to look at each patient’s hospital notes and extract
information such as age, sex, and treatments received. We will also ask patients or a family member about
the events leading up to being admitted to hospital, if these details are not clearly recorded in the notes. By
having participation from all patients we can document current services and plan for best care in the future.
Also, patients complete a psychological questionnaire (if they wish to participate in this section of the
survey), and this is returned anonymously to the researchers.
The Follow-up study
Patients who are willing to be included in the follow-up study will be asked to complete a short form
which is designed to measure how they feel about their physical functioning, social functioning,
energy/fatigue, mental health and quality of life. This will be repeated in the follow up study to allow
tracking of changes over time. Patients will also be asked about the services and care they have received
since being in hospital. By participating in this additional study we can document how well treatment
services are provided once patients have left hospital
Are there any adverse effects from the conduct of this research?
We do not expect there to be any risks or adverse effects from taking part in this research. The
investigators named below will be available to answer any questions you may have about the study either
during the study or afterwards.
Is participation voluntary?
Your participation in the CCU2003 study is voluntary. Agreement to participate in the Follow-Up study is
also completely voluntary. The very same care will be given to you whether or not you agree to participate
in either study.
Will the information collected remain confidential?
Your name, or any other details that might identify you, will not be published in the reports of the research,
but the researchers will record these details, so that the clinical information collected can be checked if
necessary. The clinical information from each patient will be combined in the study reports to give an
overall picture of how patients are cared for throughout the country. Each hospital will also be given a
report showing how the treatment given to patients in that hospital compares with that given in the country
as a whole. No details which would allow individual patients to be identified will be included in any of
these reports.
Contacting the researchers
This study is being done by the Royal College of Surgeons in Ireland in hospitals across the country. If you
have any questions the local hospital contact person is XXXXXXX.
You may also contact the main study research coordinators, XXXXXXX (01 XXXXXXX), and
XXXXXXX (01 XXXXXXX), Dept of Epidemiology and Public Health Medicine RCSI.
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Appendix E – Patient Consent Form
Patient Consent Form for CCU 2003 Survey and Follow-Up Survey
Hospital Chart No __________________ Hospital Number:
CONSENT FOR PARTICIPATION IN A SURVEY OF PATIENTS ADMITTED TO
CORONARY CARE UNITS AND INTENSIVE CARE UNITS WITH CHEST PAIN
(CCU 2003)
The nature of this study has been fully explained to me and I have read the information sheet about the
study. I have had the opportunity to ask questions about my involvement in the study. I know that my
participation in this study is completely voluntary, and that my participation (or otherwise) does not affect
my treatment in the hospital.
I, the undersigned, agree to participate in the study assessing the care of patients admitted to hospital as
described in the information sheet. I have received a copy of the consent form and information sheet for my
own records and I understand that if I have any questions I can contact the investigators listed on the
information sheet.
…………………………………………………………………………………………..
Signature                                                                                                 Date
…………………………………………………………………………………………
Name:
CONSENT FOR PARTICIPATION IN A FOLLOW-UP  STUDY OF PATIENTS ADMITTED
TO CORONARY CARE UNITS AND INTENSIVE CARE UNITS WITH CHEST PAIN
Consent to Follow-up
I agree/do not agree to be included in a list of patients who may be contacted next year as part of a follow
up study of patients who have been admitted to hospital for chest pain (Please tick box below.) I understand
that I can decide not to participate in this follow-up study at any time.
I agree to be re-contacted  
I do not agree to be re-contacted  
Signature
I confirm that I have explained the above and answered any questions the participant has about the studies.
…………………………………………………………………………………………..
Name of researcher                                                                              Date
